Insertable cardiac monitor

Information

  • Patent Grant
  • 11660035
  • Patent Number
    11,660,035
  • Date Filed
    Monday, April 20, 2020
    4 years ago
  • Date Issued
    Tuesday, May 30, 2023
    11 months ago
Abstract
Long-term electrocardiographic and physiological monitoring over a period lasting up to several years in duration can be provided through a continuously-recording insertable cardiac monitor. The sensing circuitry and the physical layout of the electrodes are specifically optimized to capture electrical signals from the propagation of low amplitude, relatively low frequency content cardiac action potentials, particularly the P-waves that are generated during atrial activation and storing samples of captured signals. In general, the ICM is intended to be implanted centrally and positioned axially and either over the sternum or slightly to either the left or right of the sternal midline in the parasternal region of the chest.
Description
FIELD

This application relates in general to electrocardiographic monitoring and, in particular, to an insertable cardiac monitor for use in performing long term electrocardiographic monitoring.


BACKGROUND

The heart emits electrical signals as a by-product of the propagation of the action potentials that trigger depolarization of heart fibers. An electrocardiogram (ECG) measures and records such electrical potentials to visually depict the electrical activity of the heart over time. Conventionally, a standardized set format 12-lead configuration is used by an ECG machine to record cardiac electrical signals from well-established traditional chest locations. Electrodes at the end of each lead are placed on the skin over the anterior thoracic region of the patient's body to the lower right and to the lower left of the sternum, on the left anterior chest, and on the limbs. Sensed cardiac electrical activity is represented by PQRSTU waveforms that can be interpreted post-ECG recordation to derive heart rate and physiology. The P-wave represents atrial electrical activity. The QRSTU components represent ventricular electrical activity.


An ECG is a tool used by physicians to diagnose heart problems and other potential health concerns. An ECG is a snapshot of heart function, typically recorded over 12 seconds, that can help diagnose rate and regularity of heartbeats, effect of drugs or cardiac devices, including pacemakers and implantable cardioverter-defibrillators (ICDs), and whether a patient has heart disease. ECGs are used in-clinic during appointments, and, as a result, are limited to recording only those heart-related aspects present at the time of recording. Sporadic conditions that may not show up during a spot ECG recording require other means to diagnose them. These disorders include fainting or syncope; rhythm disorders, such as tachyarrhythmias and bradyarrhythmias; apneic episodes; and other cardiac and related disorders. Thus, an ECG only provides a partial picture and can be insufficient for complete patient diagnosis of many cardiac disorders.


Diagnostic efficacy can be improved, when appropriate, through the use of long-term extended ECG monitoring. Recording sufficient ECG, that is of a quality sufficient to be useful in arrhythmia diagnosis, and related physiology over an extended period is challenging, and often essential to enabling a physician to identify events of potential concern. A 30-day observation day period is considered the “gold standard” of ECG monitoring, yet achieving a 30-day observation day period has proven unworkable because such ECG monitoring systems are arduous to employ, cumbersome to the patient, and excessively costly. Ambulatory monitoring in-clinic is implausible and impracticable. Nevertheless, if a patient's ECG could be recorded in an ambulatory setting, thereby allowing the patient to engage in activities of daily living, the chances of acquiring meaningful information and capturing an abnormal event while the patient is engaged in normal activities becomes more likely to be achieved.


For instance, the long-term wear of dermal ECG electrodes is complicated by skin irritation and the inability ECG electrodes to maintain continual skin contact after a day or two. Moreover, time, dirt, moisture, and other environmental contaminants, as well as perspiration, skin oil, and dead skin cells from the patient's body, can get between an ECG electrode, the non-conductive adhesive used to adhere the ECG electrode, and the skin's surface. All of these factors adversely affect electrode adhesion and the quality of cardiac signal recordings. Furthermore, the physical movements of the patient and their clothing impart various compressional, tensile, and torsional forces on the contact point of an ECG electrode, especially over long recording times, and an inflexibly fastened ECG electrode will be prone to becoming dislodged. Notwithstanding the cause of electrode dislodgment, depending upon the type of ECG monitor employed, precise re-placement of a dislodged ECG electrode may be essential to ensuring signal capture at the same fidelity. Moreover, dislodgment may occur unbeknownst to the patient, making the ECG recordings worthless. Further, some patients may have skin that is susceptible to itching or irritation, and the wearing of ECG electrodes can aggravate such skin conditions. Thus, a patient may want or need to periodically remove or replace ECG electrodes during a long-term ECG monitoring period, whether to replace a dislodged electrode, reestablish better adhesion, alleviate itching or irritation, allow for cleansing of the skin, allow for showering and exercise, or for other purpose. Such replacement or slight alteration in electrode location actually facilitates the goal of recording the ECG signal for long periods of time.


While subcutaneous ECG monitors can perform monitoring for an extended period of time, up to three years, such subcutaneous ECG monitors, because of their small size, have greater problems of demonstrating a clear and dependable P-wave. The issues related to a tiny atrial voltage are exacerbated by the small size of insertable cardiac monitors (ICMs), the signal processing limits imposed upon them by virtue of their reduced electrode size, and restricted inter-electrode spacing. Conventional subcutaneous ICMs, as well as most conventional surface ECG monitors, are notorious for poor visualization of the P-wave, which remains the primary reason that heart rhythm disorders cannot precisely be identified today from ICMs. Furthermore, even when physiologically present, the P-wave may not actually appear on an ECG because the P-wave's visibility is strongly dependent upon the signal capturing ability of the ECG recording device's sensing circuitry. This situation is further influenced by several factors, including electrode configuration, electrode surface areas and shapes, inter-electrode spacing; where the electrodes are placed on or within the body relative to the heart's atria. Further, the presence or absence of ambient noise and the means to limit the ambient noise is a key aspect of whether the low amplitude atrial signal can be seen.


Conventional ICMs are often used after diagnostic measures when dermal ECG monitors fail to identify a suspected arrhythmia. Consequently, when a physician is strongly suspicious of a serious cardiac rhythm disorder that may have caused loss of consciousness or stroke, for example, the physician will often proceed to the insertion of an ICM under the skin of the thorax. Although traditionally, the quality of the signal is limited with ICMs with respect to identifying the P-wave, the duration of monitoring is hoped to compensate for poor P-wave recording. This situation has led to a dependence on scrutiny of R-wave behavior, such as RR interval (R-wave-to-R-wave interval) behavior, often used as a surrogate for diagnosing atrial fibrillation, a potential cause of stroke. To a limited extent, this approach has some degree of value. Nevertheless, better recording of the P-wave would result in a significant diagnostic improvement, not only in the case of atrial fibrillation, but in a host of other rhythm disorders that can result in syncope or loss of consciousness, like VT or heart block.


The P-wave is the most difficult ECG signal to capture by virtue of originating in the low tissue mass atria and having both low voltage amplitude and relatively low frequency content. Notwithstanding these physiological constraints, ICMs are popular, albeit limited in their diagnostic yield. The few ICMs that are commercially available today, including the Reveal LINQ ICM, manufactured by Medtronic, Inc., Minneapolis, Minn., the BioMonitor 2 (AF and S versions), manufactured by Biotronik SE & Co. K G, Berlin, Germany, and the Abbott Confirm Rx ICM, manufactured by Abbott Laboratories, Chicago, Ill., all are uniformly limited in their abilities to clearly and consistently sense, record, and deliver the P-wave.


Typically, the current realm of ICM devices use a loop recorder where cumulative ECG data lasting for around an hour is continually overwritten unless an episode of pre-programmed interest occurs or a patient marker is manually triggered. The limited temporal window afforded by the recordation loop is yet another restriction on the evaluation of the P-wave, and related cardiac morphologies, and further compromises diagnostic opportunities.


For instance, Medtronic's Reveal LINQ ICM delivers long-term subcutaneous ECG monitoring for up to three years, depending on programming. The monitor is able to store up to 59 minutes of ECG data, include up to 30 minutes of patient-activated episodes, 27 minutes of automatically detected episodes, and two minutes of the longest atrial fibrillation (AF) episode stored since the last interrogation of the device. The focus of the device is more directed to recording duration and programming options for recording time and patient interactions rather than signal fidelity. The Reveal LINQ ICM is intended for general purpose ECG monitoring and lacks an engineering focus on P-wave visualization. Moreover, the device's recording circuitry is intended to secure the ventricular signal by capturing the R-wave, and is designed to accommodate placement over a broad range of subcutaneous implantation sites, which is usually sufficient if one is focused on the R-wave given its amplitude and frequency content, but of limited value in capturing the low-amplitude, low-frequency content P-wave. Finally, electrode spacing, surface areas, and shapes are dictated (and limited) by the physical size of the monitor's housing which is quite small, an aesthetic choice, but unrealistic with respect to capturing the P-wave.


Similar in design is the titanium housing of Biotronik's BioMonitor 2 but with a flexible silicone antenna to mount a distal electrode lead, albeit of a standardized length. This standardized length mollifies, in one parameter only, the concerns of limited inter-electrode spacing and its curbing effect on securing the P-wave. None of the other factors related to P-wave signal revelation are addressed. Therefore the quality of sensed P-waves reflects a compromise caused by closely-spaced poles that fail to consistently preserve P-wave fidelity, with the reality of the physics imposed problems of signal-to-noise ratio limitations remaining mostly unaddressed.


Therefore, a need remains for a continuously recording ECG monitor practicably capable of being worn capable of recording atrial signals reliably and that is designed for atrial activity recording.


SUMMARY

Physiological monitoring can be provided through a wearable monitor that includes two components, a flexible extended wear electrode patch and a removable reusable monitor recorder. The wearable monitor sits centrally (in the midline) on the patient's chest along the sternum oriented top-to-bottom. The placement of the wearable monitor in a location at the sternal midline (or immediately to either side of the sternum), with its unique narrow “hourglass”-like shape, benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch anywhere within the general region of the sternum. In addition, power is provided through a battery provided on the electrode patch, which avoids having to either periodically open the housing of the monitor recorder for the battery replacement, which also creates the potential for moisture intrusion and human error, or to recharge the battery, which can potentially take the monitor recorder off line for hours at a time. In addition, the electrode patch is intended to be disposable, while the monitor recorder is a reusable component. Thus, each time that the electrode patch is replaced, a fresh battery is provided for the use of the monitor recorder.


Further, long-term electrocardiographic and physiological monitoring over a period lasting up to several years in duration can be provided through a continuously-recording subcutaneous insertable cardiac monitor (ICM), such as one described in commonly-owned U.S. patent application Ser. No. 15/832,385, filed Dec. 5, 2017, pending, the disclosure of which is incorporated by reference. The sensing circuitry and the physical layout of the electrodes are specifically optimized to capture electrical signals from the propagation of low amplitude, relatively low frequency content cardiac action potentials, particularly the P-waves that are generated during atrial activation. In general, the ICM is intended to be implanted centrally and positioned axially and slightly to either the left or right of the sternal midline in the parasternal region of the chest. In one embodiment, an insertable cardiac monitor is provided. An implantable housing is made of a biocompatible material suitable for implantation within a living body. A pair of ECG sensing electrodes is provided on a ventral surface of the implantable housing with one of the ECG sensing electrodes forming a superior pole on a proximal end of the implantable housing and the other ECG sensing electrode forming an inferior pole on a distal end of the implantable housing to capture P-wave signals that are generated during atrial activation. Electronic circuitry is provided within the implantable housing and includes a microcontroller operable to execute under modular micro program control as specified in firmware. An ECG front end circuit is interfaced to the microcontroller and configured to capture the cardiac action potentials of the P-wave signals sensed by the pairing of the ECG sensing electrode. A non-volatile memory is electrically interfaced with the microcontroller and operable to continuously store samples of the cardiac action potentials of the P-wave signals. The foregoing aspects enhance ECG monitoring performance and quality facilitating long-term ECG recording, critical to accurate arrhythmia diagnosis.


Still other embodiments will become readily apparent to those skilled in the art from the following detailed description, wherein are described embodiments by way of illustrating the best mode contemplated. As will be realized, other and different embodiments are possible and the embodiments' several details are capable of modifications in various obvious respects, all without departing from their spirit and the scope. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not as restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography and physiological sensor monitor, including a monitor recorder in accordance with one embodiment, respectively fitted to the sternal region of a female patient and a male patient.



FIG. 3 is a perspective view showing an extended wear electrode patch with a monitor recorder in accordance with one embodiment inserted.



FIG. 4 is a perspective view showing the monitor recorder of FIG. 3.



FIG. 5 is a perspective view showing the extended wear electrode patch of FIG. 3 without a monitor recorder inserted.



FIG. 6 is a bottom plan view of the monitor recorder of FIG. 3.



FIG. 7 is a top view showing the flexible circuit of the extended wear electrode patch of FIG. 3 when mounted above the flexible backing.



FIG. 8 is a functional block diagram showing the component architecture of the circuitry of the monitor recorder of FIG. 3.



FIG. 9 is a functional block diagram showing the circuitry of the extended wear electrode patch of FIG. 3.



FIG. 10 is a flow diagram showing a monitor recorder-implemented method for monitoring ECG data for use in the monitor recorder of FIG. 3.



FIG. 11 is a graph showing, by way of example, a typical ECG waveform.



FIG. 12 is a diagram showing, by way of example, a subcutaneous P-wave centric insertable cardiac monitor (ICM) for long term electrocardiographic monitoring in accordance with one embodiment.



FIGS. 13 and 14 are respectively top and bottom perspective views showing the ICM of FIG. 12.



FIG. 15 is a bottom perspective view showing the ICM of FIG. 12 in accordance with a further embodiment.



FIGS. 16 and 17 are respectively top and bottom perspective views showing an ICM in accordance with a still further embodiment.



FIG. 18A and FIG. 18B are plan views showing further electrode configurations.



FIG. 19 is a functional block diagram showing the P-wave focused component architecture of the circuitry 280 of the ICM 212 of FIG. 12.





DETAILED DESCRIPTION

Physiological monitoring can be provided through a wearable monitor that includes two components, a flexible extended wear electrode patch and a removable reusable monitor recorder. FIGS. 1 and 2 are diagrams showing, by way of examples, an extended wear electrocardiography and physiological sensor monitor 12, including a monitor recorder 14 in accordance with one embodiment, respectively fitted to the sternal region of a female patient 10 and a male patient 11. The wearable monitor 12 sits centrally (in the midline) on the patient's chest along the sternum 13 oriented top-to-bottom with the monitor recorder 14 preferably situated towards the patient's head. In a further embodiment, the orientation of the wearable monitor 12 can be corrected post-monitoring, as further described infra. The electrode patch 15 is shaped to fit comfortably and conformal to the contours of the patient's chest approximately centered on the sternal midline 16 (or immediately to either side of the sternum 13). The distal end of the electrode patch 15 extends towards the Xiphoid process and, depending upon the patient's build, may straddle the region over the Xiphoid process. The proximal end of the electrode patch 15, located under the monitor recorder 14, is below the manubrium and, depending upon patient's build, may straddle the region over the manubrium.


The placement of the wearable monitor 12 in a location at the sternal midline 16 (or immediately to either side of the sternum 13) significantly improves the ability of the wearable monitor 12 to cutaneously sense cardiac electric signals, particularly the P-wave (or atrial activity) and, to a lesser extent, the QRS interval signals in the ECG waveforms that indicate ventricular activity. The sternum 13 overlies the right atrium of the heart and the placement of the wearable monitor 12 in the region of the sternal midline 13 puts the ECG electrodes of the electrode patch 15 in a location better adapted to sensing and recording P-wave signals than other placement locations, say, the upper left pectoral region. In addition, placing the lower or inferior pole (ECG electrode) of the electrode patch 15 over (or near) the Xiphoid process facilitates sensing of right ventricular activity and provides superior recordation of the QRS interval.


During use, the electrode patch 15 is first adhesed to the skin along the sternal midline 16 (or immediately to either side of the sternum 13). A monitor recorder 14 is then snapped into place on the electrode patch 15 to initiate ECG monitoring. FIG. 3 is a perspective view showing an extended wear electrode patch 15 with a monitor recorder 14 in accordance with one embodiment inserted. The body of the electrode patch 15 is preferably constructed using a flexible backing 20 formed as an elongated strip 21 of wrap knit or similar stretchable material with a narrow longitudinal mid-section 23 evenly tapering inward from both sides. A pair of cut-outs 22 between the distal and proximal ends of the electrode patch 15 create a narrow longitudinal midsection 23 or “isthmus” and defines an elongated “hourglass”-like shape, when viewed from above.


The electrode patch 15 incorporates features that significantly improve wearability, performance, and patient comfort throughout an extended monitoring period. During wear, the electrode patch 15 is susceptible to pushing, pulling, and torqueing movements, including compressional and torsional forces when the patient bends forward, and tensile and torsional forces when the patient leans backwards. To counter these stress forces, the electrode patch 15 incorporates strain and crimp reliefs, such as described in commonly-assigned U.S. Patent, entitled “Extended Wear Electrocardiography Patch,” U.S. Pat. No. 9,545,204, issued on Jan. 17, 2017, the disclosure of which is incorporated by reference. In addition, the cut-outs 22 and longitudinal midsection 23 help minimize interference with and discomfort to breast tissue, particularly in women (and gynecomastic men). The cut-outs 22 and longitudinal midsection 23 further allow better conformity of the electrode patch 15 to sternal bowing and to the narrow isthmus of flat skin that can occur along the bottom of the intermammary cleft between the breasts, especially in buxom women. The cut-outs 22 and longitudinal midsection 23 help the electrode patch 15 fit nicely between a pair of female breasts in the intermammary cleft. Still other shapes, cut-outs and conformities to the electrode patch 15 are possible.


The monitor recorder 14 removably and reusably snaps into an electrically non-conductive receptacle 25 during use. The monitor recorder 14 contains electronic circuitry for recording and storing the patient's electrocardiography as sensed via a pair of ECG electrodes provided on the electrode patch 15, as further described infra beginning with reference to FIG. 8. The non-conductive receptacle 25 is provided on the top surface of the flexible backing 20 with a retention catch 26 and tension clip 27 molded into the non-conductive receptacle 25 to conformably receive and securely hold the monitor recorder 14 in place.


The monitor recorder 14 includes a sealed housing that snaps into place in the non-conductive receptacle 25. FIG. 4 is a perspective view showing the monitor recorder 14 of FIG. 3. The sealed housing 50 of the monitor recorder 14 intentionally has a rounded isosceles trapezoidal-like shape 52, when viewed from above, such as described in commonly-assigned U.S. Design Patent, entitled “Electrocardiography Monitor,” U.S. Design No. D717955, issued on Nov. 18, 2014, the disclosure of which is incorporated by reference. The edges 51 along the top and bottom surfaces are rounded for patient comfort. The sealed housing 50 is approximately 47 mm long, 23 mm wide at the widest point, and 7 mm high, excluding a patient-operable tactile-feedback button 55. The sealed housing 50 can be molded out of polycarbonate, ABS, or an alloy of those two materials. The button 55 is waterproof and the button's top outer surface is molded silicon rubber or similar soft pliable material. A retention detent 53 and tension detent 54 are molded along the edges of the top surface of the housing 50 to respectively engage the retention catch 26 and the tension clip 27 molded into non-conductive receptacle 25. Other shapes, features, and conformities of the sealed housing 50 are possible.


The electrode patch 15 is intended to be disposable. The monitor recorder 14, however, is reusable and can be transferred to successive electrode patches 15 to ensure continuity of monitoring. The placement of the wearable monitor 12 in a location at the sternal midline 16 (or immediately to either side of the sternum 13) benefits long-term extended wear by removing the requirement that ECG electrodes be continually placed in the same spots on the skin throughout the monitoring period. Instead, the patient is free to place an electrode patch 15 anywhere within the general region of the sternum 13.


As a result, at any point during ECG monitoring, the patient's skin is able to recover from the wearing of an electrode patch 15, which increases patient comfort and satisfaction, while the monitor recorder 14 ensures ECG monitoring continuity with minimal effort. A monitor recorder 14 is merely unsnapped from a worn out electrode patch 15, the worn out electrode patch 15 is removed from the skin, a new electrode patch 15 is adhered to the skin, possibly in a new spot immediately adjacent to the earlier location, and the same monitor recorder 14 is snapped into the new electrode patch 15 to reinitiate and continue the ECG monitoring.


During use, the electrode patch 15 is first adhered to the skin in the sternal region. FIG. 5 is a perspective view showing the extended wear electrode patch 15 of FIG. 3 without a monitor recorder 14 inserted. A flexible circuit 32 is adhered to each end of the flexible backing 20. A distal circuit trace 33 and a proximal circuit trace (not shown) electrically couple ECG electrodes (not shown) to a pair of electrical pads 34. The electrical pads 34 are provided within a moisture-resistant seal 35 formed on the bottom surface of the non-conductive receptacle 25. When the monitor recorder 14 is securely received into the non-conductive receptacle 25, that is, snapped into place, the electrical pads 34 interface to electrical contacts (not shown) protruding from the bottom surface of the monitor recorder 14, and the moisture-resistant seal 35 enables the monitor recorder 14 to be worn at all times, even during bathing or other activities that could expose the monitor recorder 14 to moisture.


In addition, a battery compartment 36 is formed on the bottom surface of the non-conductive receptacle 25, and a pair of battery leads (not shown) electrically interface the battery to another pair of the electrical pads 34. The battery contained within the battery compartment 35 can be replaceable, rechargeable or disposable.


The monitor recorder 14 draws power externally from the battery provided in the non-conductive receptacle 25, thereby uniquely obviating the need for the monitor recorder 14 to carry a dedicated power source. FIG. 6 is a bottom plan view of the monitor recorder 14 of FIG. 3. A cavity 58 is formed on the bottom surface of the sealed housing 50 to accommodate the upward projection of the battery compartment 36 from the bottom surface of the non-conductive receptacle 25, when the monitor recorder 14 is secured in place on the non-conductive receptacle 25. A set of electrical contacts 56 protrude from the bottom surface of the sealed housing 50 and are arranged in alignment with the electrical pads 34 provided on the bottom surface of the non-conductive receptacle 25 to establish electrical connections between the electrode patch 15 and the monitor recorder 14. In addition, a seal coupling 57 circumferentially surrounds the set of electrical contacts 56 and securely mates with the moisture-resistant seal 35 formed on the bottom surface of the non-conductive receptacle 25.


The placement of the flexible backing 20 on the sternal midline 16 (or immediately to either side of the sternum 13) also helps to minimize the side-to-side movement of the wearable monitor 12 in the left- and right-handed directions during wear. To counter the dislodgment of the flexible backing 20 due to compressional and torsional forces, a layer of non-irritating adhesive, such as hydrocolloid, is provided at least partially on the underside, or contact, surface of the flexible backing 20, but only on the distal end 30 and the proximal end 31. As a result, the underside, or contact surface of the longitudinal midsection 23 does not have an adhesive layer and remains free to move relative to the skin. Thus, the longitudinal midsection 23 forms a crimp relief that respectively facilitates compression and twisting of the flexible backing 20 in response to compressional and torsional forces. Other forms of flexible backing crimp reliefs are possible. Unlike the flexible backing 20, the flexible circuit 32 is only able to bend and cannot stretch in a planar direction. The flexible circuit 32 can be provided either above or below the flexible backing 20. FIG. 7 is a top view showing the flexible circuit 32 of the extended wear electrode patch 15 of FIG. 3 when mounted above the flexible backing 20. A distal ECG electrode 38 and proximal ECG electrode 39 are respectively coupled to the distal and proximal ends of the flexible circuit 32. A strain relief 40 is defined in the flexible circuit 32 at a location that is partially underneath the battery compartment 36 when the flexible circuit 32 is affixed to the flexible backing 20. The strain relief 40 is laterally extendable to counter dislodgment of the ECG electrodes 38, 39 due to tensile and torsional forces. A pair of strain relief cutouts 41 partially extend transversely from each opposite side of the flexible circuit 32 and continue longitudinally towards each other to define in ‘S’-shaped pattern, when viewed from above. The strain relief respectively facilitates longitudinal extension and twisting of the flexible circuit 32 in response to tensile and torsional forces. Other forms of circuit board strain relief are possible. ECG monitoring and other functions performed by the monitor recorder 14 are provided through a micro controlled architecture. FIG. 8 is a functional block diagram showing the component architecture of the circuitry 60 of the monitor recorder 14 of FIG. 3. The circuitry 60 is externally powered through a battery provided in the non-conductive receptacle 25 (shown in FIG. 5). Both power and raw ECG signals, which originate in the pair of ECG electrodes 38, 39 (shown in FIG. 7) on the distal and proximal ends of the electrode patch 15, are received through an external connector 65 that mates with a corresponding physical connector on the electrode patch 15. The external connector 65 includes the set of electrical contacts 56 that protrude from the bottom surface of the sealed housing 50 and which physically and electrically interface with the set of pads 34 provided on the bottom surface of the non-conductive receptacle 25. The external connector includes electrical contacts 56 for data download, microcontroller communications, power, analog inputs, and a peripheral expansion port. The arrangement of the pins on the electrical connector 65 of the monitor recorder 14 and the device into which the monitor recorder 14 is attached, whether an electrode patch 15 or download station (not shown), follow the same electrical pin assignment convention to facilitate interoperability. The external connector 65 also serves as a physical interface to a download station that permits the retrieval of stored ECG monitoring data, communication with the monitor recorder 14, and performance of other functions.


Operation of the circuitry 60 of the monitor recorder 14 is managed by a microcontroller 61. The micro-controller 61 includes a program memory unit containing internal flash memory that is readable and writeable. The internal flash memory can also be programmed externally. The micro-controller 61 draws power externally from the battery provided on the electrode patch 15 via a pair of the electrical contacts 56. The microcontroller 61 connects to the ECG front end circuit 63 that measures raw cutaneous electrical signals and generates an analog ECG signal representative of the electrical activity of the patient's heart over time.


The circuitry 60 of the monitor recorder 14 also includes a flash memory 62, which the micro-controller 61 uses for storing ECG monitoring data and other physiology and information. The flash memory 62 also draws power externally from the battery provided on the electrode patch 15 via a pair of the electrical contacts 56. Data is stored in a serial flash memory circuit, which supports read, erase and program operations over a communications bus. The flash memory 62 enables the microcontroller 61 to store digitized ECG data. The communications bus further enables the flash memory 62 to be directly accessed externally over the external connector 65 when the monitor recorder 14 is interfaced to a download station.


The circuitry 60 of the monitor recorder 14 further includes an actigraphy sensor 64 implemented as a 3-axis accelerometer. The accelerometer may be configured to generate interrupt signals to the microcontroller 61 by independent initial wake up and free fall events, as well as by device position. In addition, the actigraphy provided by the accelerometer can be used during post-monitoring analysis to correct the orientation of the monitor recorder 14 if, for instance, the monitor recorder 14 has been inadvertently installed upside down, that is, with the monitor recorder 14 oriented on the electrode patch 15 towards the patient's feet, as well as for other event occurrence analyses.


The microcontroller 61 includes an expansion port that also utilizes the communications bus. External devices, separately drawing power externally from the battery provided on the electrode patch 15 or other source, can interface to the microcontroller 61 over the expansion port in half duplex mode. For instance, an external physiology sensor can be provided as part of the circuitry 60 of the monitor recorder 14, or can be provided on the electrode patch 15 with communication with the micro-controller 61 provided over one of the electrical contacts 56. The physiology sensor can include an SpO2 sensor, blood pressure sensor, temperature sensor, respiratory rate sensor, glucose sensor, airflow sensor, volumetric pressure sensing, or other types of sensor or telemetric input sources. In a further embodiment, a wireless interface for interfacing with other wearable (or implantable) physiology monitors, as well as data offload and programming, can be provided as part of the circuitry 60 of the monitor recorder 14, or can be provided on the electrode patch 15 with communication with the micro-controller 61 provided over one of the electrical contacts 56.


Finally, the circuitry 60 of the monitor recorder 14 includes patient-interfaceable components, including a tactile feedback button 66, which a patient can press to mark events or to perform other functions, and a buzzer 67, such as a speaker, magnetic resonator or piezoelectric buzzer. The buzzer 67 can be used by the microcontroller 61 to output feedback to a patient such as to confirm power up and initiation of ECG monitoring. Still other components as part of the circuitry 60 of the monitor recorder 14 are possible. While the monitor recorder 14 operates under micro control, most of the electrical components of the electrode patch 15 operate passively. FIG. 9 is a functional block diagram showing the circuitry 70 of the extended wear electrode patch 15 of FIG. 3. The circuitry 70 of the electrode patch 15 is electrically coupled with the circuitry 60 of the monitor recorder 14 through an external connector 74. The external connector 74 is terminated through the set of pads 34 provided on the bottom of the non-conductive receptacle 25, which electrically mate to corresponding electrical contacts 56 protruding from the bottom surface of the sealed housing 50 to electrically interface the monitor recorder 14 to the electrode patch 15.


The circuitry 70 of the electrode patch 15 performs three primary functions. First, a battery 71 is provided in a battery compartment formed on the bottom surface of the non-conductive receptacle 25. The battery 71 is electrically interfaced to the circuitry 60 of the monitor recorder 14 as a source of external power. The unique provisioning of the battery 71 on the electrode patch 15 provides several advantages. First, the locating of the battery 71 physically on the electrode patch 15 lowers the center of gravity of the overall wearable monitor 12 and thereby helps to minimize shear forces and the effects of movements of the patient and clothing. Moreover, the housing 50 of the monitor recorder 14 is sealed against moisture and providing power externally avoids having to either periodically open the housing 50 for the battery replacement, which also creates the potential for moisture intrusion and human error, or to recharge the battery, which can potentially take the monitor recorder 14 off line for hours at a time. In addition, the electrode patch 15 is intended to be disposable, while the monitor recorder 14 is a reusable component. Each time that the electrode patch 15 is replaced, a fresh battery is provided for the use of the monitor recorder 14, which enhances ECG monitoring performance quality and duration of use. Finally, the architecture of the monitor recorder 14 is open, in that other physiology sensors or components can be added by virtue of the expansion port of the microcontroller 61. Requiring those additional sensors or components to draw power from a source external to the monitor recorder 14 keeps power considerations independent of the monitor recorder 14. Thus, a battery of higher capacity could be introduced when needed to support the additional sensors or components without effecting the monitor recorders circuitry 60.


Second, the pair of ECG electrodes 38, 39 respectively provided on the distal and proximal ends of the flexible circuit 32 are electrically coupled to the set of pads 34 provided on the bottom of the non-conductive receptacle 25 by way of their respective circuit traces 33, 37. The signal ECG electrode 39 includes a protection circuit 72, which is an inline resistor that protects the patient from excessive leakage current.


Last, in a further embodiment, the circuitry 70 of the electrode patch 15 includes a cryptographic circuit 73 to authenticate an electrode patch 15 for use with a monitor recorder 14. The cryptographic circuit 73 includes a device capable of secure authentication and validation. The cryptographic device 73 ensures that only genuine, non-expired, safe, and authenticated electrode patches 15 are permitted to provide monitoring data to a monitor recorder 14.


The monitor recorder 14 continuously monitors the patient's heart rate and physiology. FIG. 10 is a flow diagram showing a monitor recorder-implemented method 100 for monitoring ECG data for use in the monitor recorder 14 of FIG. 3. Initially, upon being connected to the set of pads 34 provided with the non-conductive receptacle 25 when the monitor recorder 14 is snapped into place, the microcontroller 61 executes a power up sequence (step 101). During the power up sequence, the voltage of the battery 71 is checked, the state of the flash memory 62 is confirmed, both in terms of operability check and available capacity, and microcontroller operation is diagnostically confirmed. In a further embodiment, an authentication procedure between the microcontroller 61 and the electrode patch 15 are also performed.


Following satisfactory completion of the power up sequence, an iterative processing loop (steps 102-109) is continually executed by the microcontroller 61. During each iteration (step 102) of the processing loop, the ECG frontend 63 (shown in FIG. 8) continually senses the cutaneous ECG electrical signals (step 103) via the ECG electrodes 38, 29 and is optimized to maintain the integrity of the P-wave. A sample of the ECG signal is read (step 104) by the microcontroller 61 by sampling the analog ECG signal output front end 63. FIG. 11 is a graph showing, by way of example, a typical ECG waveform 110. The x-axis represents time in approximate units of tenths of a second. The y-axis represents cutaneous electrical signal strength in approximate units of millivolts. The P-wave 111 has a smooth, normally upward, that is, positive, waveform that indicates atrial depolarization. The QRS complex usually begins with the downward deflection of a Q wave 112, followed by a larger upward deflection of an R-wave 113, and terminated with a downward waveform of the S wave 114, collectively representative of ventricular depolarization. The T wave 115 is normally a modest upward waveform, representative of ventricular depolarization, while the U wave 116, often not directly observable, indicates the recovery period of the Purkinje conduction fibers.


Sampling of the R-to-R interval enables heart rate information derivation. For instance, the R-to-R interval represents the ventricular rate and rhythm, while the P-to-P interval represents the atrial rate and rhythm. Importantly, the PR interval is indicative of atrioventricular (AV) conduction time and abnormalities in the PR interval can reveal underlying heart disorders, thus representing another reason why the P-wave quality achievable by the extended wear ambulatory electrocardiography and physiological sensor monitor described herein is medically unique and important. The long-term observation of these ECG indicia, as provided through extended wear of the wearable monitor 12, provides valuable insights to the patient's cardiac function and overall well-being.


Each sampled ECG signal, in quantized and digitized form, is temporarily staged in buffer (step 105), pending compression preparatory to storage in the flash memory 62 (step 106). Following compression, the compressed ECG digitized sample is again buffered (step 107), then written to the flash memory 62 (step 108) using the communications bus. Processing continues (step 109), so long as the monitoring recorder 14 remains connected to the electrode patch 15 (and storage space remains available in the flash memory 62), after which the processing loop is exited and execution terminates. Still other operations and steps are possible.


In a further embodiment, the method 100 described above with reference to FIG. 10 can also be implemented by a continuously-recording subcutaneous insertable cardiac monitor (ICM), such as one described in commonly-owned U.S. patent application Ser. No. 15/832,385, filed Dec. 5, 2017, pending, the disclosure of which is incorporated by reference. The ICM can be used for conducting a long-term electrocardiographic and physiological monitoring over a period lasting up to several years in duration. FIG. 12 is a diagram showing, by way of example, a subcutaneous P-wave centric ICM 212 for long term electrocardiographic monitoring in accordance with one embodiment. The ICM 212 is implanted in the parasternal region 211 of a patient 10. The sensing circuitry and components, compression algorithms, and the physical layout of the electrodes are specifically optimized to capture electrical signals from the propagation of low amplitude, relatively low frequency content cardiac action potentials, particularly the P-waves generated during atrial activation. The position and placement of the ICM 212 coupled to engineering considerations that optimize the ICM's sensing circuitry, discussed infra, aid in demonstrating the P-wave clearly.


Implantation of a P-wave centric ICM 212 in the proper subcutaneous site facilitates the recording of high quality ECG data with a good delineation of the P-wave. In general, the ICM 212 is intended to be implanted anteriorly and be positioned axially and slightly to either the right or left of the sternal midline in the parasternal region 211 of the chest, or if sufficient subcutaneous fat exists, directly over the sternum. Optimally, the ICM 212 is implanted in a location left parasternally to bridge the left atrial appendage. However, either location to the right or left of the sternal midline is acceptable; placement of the device, if possible, should bridge the vertical height of the heart, which lies underneath the sternum 203, thereby placing the ICM 212 in close proximity to the anterior right atrium and the left atrial appendage that lie immediately beneath.


The ICM 212 is shaped to fit comfortably within the body under the skin and to conform to the contours of the patient's parasternal region 211 when implanted immediately to either side of the sternum 203, but could be implanted in other locations of the body. In most adults, the proximal end 213 of the ICM 212 is generally positioned below the manubrium 8 but, depending upon patient's vertical build, the ICM 212 may actually straddle the region over the manubrium 8. The distal end 214 of the ICM 212 generally extends towards the xiphoid process 9 and lower sternum but, depending upon the patient's build, may actually straddle the region over or under the xiphoid process 9, lower sternum and upper abdomen.


Although internal tissues, body structures, and tissue boundaries can adversely affect the current strength and signal fidelity of all body surface potentials, subsurface low amplitude cardiac action potentials, particularly P-wave signals with a normative amplitude of less than 0.25 millivolts (mV) and a normative duration of less than 120 milliseconds (ms), are most apt to be negatively impacted by these factors. The atria, which generate the P wave, are mostly located posteriorly within the thoracic cavity (with the exception of the anterior right atrium, right atrial appendage and left atrial appendage). The majority of the left atrium constitutes the portion of the heart furthest away from the surface of the skin on the chest and harbors the atrial tissue most likely to be the source of serious arrhythmias, like atrial fibrillation. Conversely, the ventricles, which generate larger amplitude signals, are located anteriorly as in the case of the anterior right ventricle and most of the anterior left ventricle situated relatively close to the skin surface of the central and left anterior chest. These factors, together with larger size and more powerful impulse generation from the ventricles, contribute to the relatively larger amplitudes of ventricular waveforms.


Nevertheless, as explained supra, both the P-wave and the R-wave are required for the physician to make a proper rhythm diagnosis from the dozens of arrhythmias that can occur. Yet, the quality of P-waves is more susceptible to weakening from distance and the intervening tissues and structures and from signal attenuation and signal processing than the high voltage waveforms associated with ventricular activation. The added value of avoiding further signal attenuation resulting from dermal impedance makes a subcutaneous P-wave centric ICM even more likely to match, or even outperform dermal ambulatory monitors designed to analogous engineering considerations and using similar sensing circuitry and components, compression algorithms, and physical layout of electrodes, such as described in U.S. Pat. No. 9,545,204, issued Jan. 217, 20217 to Bishay et al.; U.S. Pat. No. 9,730,593, issued Aug. 15, 20217 to Felix et al.; U.S. Pat. No. 9,700,227, issued Jul. 11, 20217 to Bishay et al.; U.S. Pat. No. 9,7217,433, issued Aug. 1, 20217 to Felix et al.; and U.S. Pat. No. 9,615,763, issued Apr. 11, 20217 to Felix et al., the disclosures of which are incorporated by reference.


The ICM 212 can be implanted in the patient's chest using, for instance, a minimally invasive subcutaneous implantation instrument or other suitable surgical implement. The ICM 212 is positioned slightly to the right or left of midline, covering the center third of the chest, roughly between the second and sixth ribs, approximately spanning between the level of the manubrium 8 and the level of the xiphoid process 9 on the inferior border of the sternum 203, depending upon the vertical build of the patient 210.


During monitoring, the amplitude and strength of action potentials sensed by an ECG devices, including dermal ECG monitors and ICMs, can be affected to varying degrees by cardiac, cellular, extracellular, vector of current flow, and physical factors, like obesity, dermatitis, lung disease, large breasts, and high impedance skin, as can occur in dark-skinned individuals. Performing ECG sensing subcutaneously in the parasternal region 211 significantly improves the ability of the ICM 212 to counter some of the effects of these factors, particularly high skin impedance and impedance from subcutaneous fat. Thus, the ICM 212 exhibits superior performance when compared to conventional dermal ECG monitors to existing implantable loop recorders, ICMs, and other forms of implantable monitoring devices by virtue of its engineering and proven P-wave documentation above the skin, as discussed in W. M. Smith et al., “Comparison of diagnostic value using a small, single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours,” Am. Heart J., Mar. 20217; 2185:67-73, the disclosure of which is incorporated by reference.


Moreover, the sternal midline implantation location in the parasternal region 211 allows the ICM's electrodes to record an ECG of optimal signal quality from a location immediately above the strongest signal-generating aspects of the atrial. Signal quality is improved further in part because cardiac action potential propagation travels simultaneously along a north-to-south and right-to-left vector, beginning high in the right atrium and ultimately ending in the posterior and lateral region of the left ventricle. Cardiac depolarization originates high in the right atrium in the SA node before concurrently spreading leftward towards the left atrium and inferiorly towards the atrioventricular (AV) node. On the proximal end 213, the ECG electrodes of the ICM 212 are subcutaneously positioned with the upper or superior pole (ECG electrode) slightly to the right or left of the sternal midline in the region of the manubrium 8 and, on the distal end 214, the lower or inferior pole (ECG electrode) is similarly situated slightly to the right or left of the sternal midline in the region of the xiphoid process 9 and lower sternum 203. The ECG electrodes of the ICM 212 are placed primarily in a north-to-south orientation along the sternum 203 that corresponds to the north-to-south waveform vector exhibited during atrial activation. This orientation corresponds to the aVF lead used in a conventional 12-lead ECG that is used to sense positive or upright P-waves. In addition, the electrode spacing and the electrodes' shapes and surface areas mimic the electrodes used in the ICM's dermal cousin, designed as part of the optimal P-wave sensing electrode configuration, such as provided with the dermal ambulatory monitors cited supra.


Despite the challenges faced in capturing low amplitude cardiac action potentials, the ICM 212 is able to operate effectively using only two electrodes that are strategically sized and placed in locations ideally suited to high fidelity P-wave signal acquisition. This approach has been shown to clinically outperform more typical multi-lead monitors because of the improved P-wave clarity, as discussed in W. M. Smith et al., cited supra. FIGS. 13 and 14 are respectively top and bottom perspective views showing the ICM 212 of FIG. 1. Physically, the ICM 212 is constructed with a hermetically sealed implantable housing 215 with at least one ECG electrode forming a superior pole on the proximal end 213 and at least one ECG electrode forming an inferior pole on the distal end 214.


When implanted, the housing 215 is oriented most cephalad. The housing 215 is constructed of titanium, stainless steel or other biocompatible material. The housing 215 contains the sensing, recordation and interfacing circuitry of the ICM 212, plus a long life battery. A wireless antenna is integrated into or within the housing 215 and can be positioned to wrap around the housing's internal periphery or location suited to signal reception. Other wireless antenna placement or integrations are possible.


Physically, the ICM 212 has four ECG electrodes 216, 217, 218, 219. There could also be additional ECG electrodes, as discussed infra. The ECG electrodes include two ventral (or dorsal) ECG electrodes 218, 219 and two wraparound ECG electrodes 216, 217. One ventral ECG electrode 218 is formed on the proximal end 213 and one ventral ECG electrode 219 is formed on the distal end 214. One wraparound ECG electrode 216 is formed circumferentially about the proximal end 213 and one wraparound ECG electrode 217 is formed circumferentially about the distal end 214. Each wraparound ECG electrode 216, 217 is electrically insulated from its respective ventral ECG electrode 218, 219 by a periphery 220, 221.


The four ECG electrodes 216, 217, 218, 219 are programmatically controlled by a microcontroller through onboard firmware programming to enable a physician to choose from several different electrode configurations that vary the electrode surface areas, shapes, and inter-electrode spacing. The sensing circuitry can be programmed, either pre-implant or in situ, to use different combinations of the available ECG electrodes (and thereby changing electrode surface areas, shapes, and inter-electrode spacing), including pairing the two ventral ECG electrodes 216, 217, the two wraparound ECG electrodes 218, 219, or one ventral ECG electrode 216, 217 with one wraparound ECG electrode 218, 219 located on the opposite end of the housing 215. In addition, the periphery 220, 221 can be programmatically controlled to logically combine the wraparound ECG electrode 216, 217 on one end of the ICM 212 with its corresponding ventral ECG electrode 218, 219 to form a single virtual ECG electrode with larger surface area and shape. (Although electronically possible, the two ECG electrodes that are only on one end of the ICM 212, for instance, wraparound ECG electrode 216 and ventral ECG electrode 218, could be paired; however, the minimal inter-electrode spacing would likely yield a signal of poor fidelity in most situations.)


In a further embodiment, the housing 215 and contained circuitry can be provided as a standalone ICM core assembly to which a pair of compatible ECG electrodes can be operatively coupled to form a full implantable ICM device.


Other ECG electrode configurations are possible. For instance, additional ECG electrodes can be provided to increase the number of possible electrode configurations, all of which are to ensure better P-wave resolution. FIG. 15 is a bottom perspective view showing the ICM 212 of FIG. 12 in accordance with a further embodiment. An additional pair of ventral ECG electrodes 222, 223 are included on the housing's ventral surface. These ventral ECG electrodes 222, 223 are spaced closer together than the ventral ECG electrodes 218, 219 on the ends of the housing 215 and a physician can thus choose to pair the two inner ventral ECG electrodes 222, 223 by themselves to allow for minimal electrode-to-electrode spacing, or with the other ECG electrodes 216, 217, 218, 219 to vary electrode surface areas, shapes, and inter-electrode spacing even further to explore optimal configurations to acquire the P-wave.


Other housing configurations of the ICM are possible. For instance, the housing of the ICM can be structured to enhance long term comfort and fitment, and to accommodate a larger long life battery or more circuitry or features, including physiologic sensors, to provide additional functionality. FIGS. 16 and 17 are respectively top and bottom perspective views showing an ICM 230 in accordance with a still further embodiment. The ICM 230 has a housing 231 with a tapered extension 232 that is terminated on the distal end with an electrode 234. On a proximal end, the housing 231 includes a pair of ECG electrodes electrically insulated by a periphery 237 that include a ventral ECG electrode 233 and a wraparound ECG electrode 234. In addition, a ventral ECG electrode 236 is oriented on the housing's distal end before the tapered extension 232. Still other housing structures and electrode configurations are possible.


In general, the basic electrode layout is sufficient to sense cardiac action potentials in a wide range of patients. Differences in thoracic tissue density and skeletal structure from patient to patient, though, can affect the ability of the sensing electrodes to efficaciously capture action potential signals, yet the degree to which signal acquisition is affected may not be apparent until after an ICM has been implanted and deployed, when the impacts of the patient's physical constitution and his patterns of mobility and physical movement on ICM monitoring can be fully assessed.


In further embodiments, the electrodes can be configured post-implant to allow the ICM to better adapt to a particular patient's physiology. For instance, electrode configurations having more than two sensing electrodes are possible. FIG. 18A and FIG. 18B are plan views showing further electrode configurations. Referring first to FIG. 18A, a single disc ECG electrode 240 could be bifurcated to form a pair of half-circle ECG electrodes 241, 242 that could be programmatically selected or combined to accommodate a particular patients ECG signal characteristics post-ICM implant. Referring next to FIG. 18B, a single disc ECG electrode 245 could be divided into three sections, a pair of crescent-shaped ECG electrodes 246, 247 surrounding a central semicircular ECG electrode 248 that could similarly be programmatically selected or combined. Still other ECG electrode configurations are possible.


ECG monitoring and other functions performed by the ICM 212 are provided through a micro controlled architecture. FIG. 19 is a functional block diagram showing the P-wave focused component architecture of the circuitry 280 of the ICM 212 of FIG. 12. The circuitry 280 is powered through the long life battery 21 provided in the housing 215, which can be a direct current battery. Operation of the circuitry 280 of the ICM 212 is managed by a microcontroller 281, such as the EFM32 Tiny Gecko 32-bit microcontroller, manufactured by Silicon Laboratories Inc., Austin, Tex. The microcontroller 281 has flexible energy management modes and includes a direct memory access controller and built-in analog-to-digital and digital-to-analog converters (ADC and DAC, respectively). The microcontroller 281 also includes a program memory unit containing internal flash memory (not shown) that is readable, writeable, and externally programmable.


The microcontroller 281 operates under modular micro program control as specified in firmware stored in the internal flash memory. The microcontroller 281 draws power from the battery provided in the housing 215 and connects to the ECG front end circuit 63. The front end circuit 63 measures raw subcutaneous electrical signals using a driven reference signal that eliminates common mode noise, as further described infra.


The circuitry 280 of the ICM 212 also includes a flash memory 282 external to the microcontroller 281, which the microcontroller 281 uses for continuously storing samples of ECG monitoring signal data and other physiology, such as respiratory rate, blood oxygen saturation level (SpO2), blood pressure, temperature sensor, and physical activity, and device and related information. The flash memory 282 also draws power from the battery provided in the housing 215. Data is stored in a serial flash memory circuit, which supports read, erase and program operations over a communications bus. The flash memory 282 enables the microcontroller 281 to store digitized ECG data. The communications bus further enables the flash memory 282 to be directly accessed wirelessly through a transceiver 285 coupled to an antenna 217 built into (or provided with) the housing 215. The transceiver 285 can be used for wirelessly interfacing over Bluetooth or other types of wireless technologies for exchanging data over a short distance with a paired mobile device, including smartphones and smart watches, that are designed to communicate over a public communications infrastructure, such as a cellular communications network, and, in a further embodiment, other wearable (or implantable) physiology monitors, such as activity trackers worn on the wrist or body. Other types of device pairings are possible, including with a desktop computer or purpose-built bedside monitor. The transceiver 285 can be used to offload stored ECG monitoring data and other physiology data and information and for device firmware reprogramming. In a further embodiment, the flash memory 282 can be accessed through an inductive coupling (not shown).


The microcontroller 281 includes functionality that enables the acquisition of samples of analog ECG signals, which are converted into a digital representation, implementing the method 100 described supra with reference to FIG. 10. In one mode, the microcontroller 281 implements a loop recorder feature that will acquire, sample, digitize, signal process, and store digitized ECG data into available storage locations in the flash memory 282 until all memory storage locations are filled, after which existing stored digitized ECG data will either be overwritten through a sliding window protocol, albeit at the cost of potentially losing the stored data that was overwritten, if not previously downloaded, or transmitted wirelessly to an external receiver to unburden the flash memory. In another mode, the stored digitized ECG data can be maintained permanently until downloaded or erased to restore memory capacity. Data download or erasure can also occur before all storage locations are filled, which would free up memory space sooner, albeit at the cost of possibly interrupting monitoring while downloading or erasure is performed. Still other modes of data storage and capacity recovery are possible.


The circuitry 280 of the ICM 212 can include functionality to programmatically select pairings of sensing electrodes when the ICM 212 is furnished with three or more electrodes. In a further embodiment, multiple sensing electrodes could be provided on the ICM 212 to provide a physician the option of fine-tuning the sensing dipole (or tripole or multipole) in situ by parking active electrodes and designating any remaining electrodes inert. The pairing selection can be made remotely through an inductive coupling or by the transceiver 285 via, for instance, a paired mobile device, as further described infra. Thus, the sensing electrode configuration, including number of electrodes, electrode-to-electrode spacing, and electrode size, shape, surface area, and placement, can be modified at any time during the implantation of the ICM 212.


In a further embodiment, the circuitry 280 of the ICM 212 can include an actigraphy sensor 284 implemented as a 3-axis accelerometer. The accelerometer may be configured to generate interrupt signals to the microcontroller 281 by independent initial wake up and free fall events, as well as by device position. In addition, the actigraphy provided by the accelerometer can be used during post-monitoring analysis to correct the orientation of the ICM 212 if, for instance, the ICM 212 has been inadvertently implanted upside down, that is, with the ICM's housing oriented caudally, as well as for other event occurrence analyses.


In a still further embodiment, the circuitry 280 of the ICM 212 can include one or more physiology sensors. For instance, a physiology sensor can be provided as part of the circuitry 280 of the ICM 212, or can be provided on the electrode assembly 214 with communication with the microcontroller 281 provided through a circuit trace. The physiology sensor can include an SpO2 sensor, blood pressure sensor, temperature sensor, respiratory rate sensor, glucose sensor, airflow sensor, volumetric pressure sensing, or other types of sensor or telemetric input sources.


In a yet further embodiment, firmware with programming instructions, including machine learning and other forms of artificial intelligence-originated instructions, can be downloaded into the microcontroller's internal flash memory.


The firmware can include heuristics to signal patient and physician with alerts over health conditions or arrhythmias of selected medical concern, such as where a heart pattern particular to the patient is identified and the ICM 212 is thereby reprogrammed to watch for a reoccurrence of that pattern, after which an alert will be generated and sent to the physician (or other caregiver) through the transceiver 285 via, for instance, a paired mobile device. Similarly, the firmware can include heuristics that can be downloaded to the ICM 212 to actively identify or narrow down a pattern (or even the underlying cause) of sporadic cardiac conditions, for instance, atrial tachycardia (AT), atrial fibrillation (AF), atrial flutter (AFL), AV node reciprocating tachycardia, ventricular tachycardia (VT), sinus bradycardia, asystole, complete heart block, and other cardiac arrhythmias, again, after which an alert will be generated and sent to the physician (or other caregiver) through the transceiver 285. For instance, an alert that includes a compressed ECG digitized sample can also be wirelessly transmitted by the ICM 212 upon the triggering of a preset condition, such as an abnormally low heart rate in excess of 170 beats per minute (bpm), an abnormally low heart rate falling below 30 bpm, or AF detected by onboard analysis of RR interval variability by the microcontroller 281. Finally, a similar methodology of creating firmware programming tailored to the monitoring and medical diagnostic needs of a specific patient (or patient group or general population) can be used for other conditions or symptoms, such as syncope, palpitations, dizziness and giddiness, unspecified convulsions, abnormal ECG, transient cerebral ischemic attacks and related syndromes, cerebral infarction, occlusion and stenosis of pre-cerebral and cerebral arteries not resulting in cerebral infarction personal history of transient ischemic attack, and cerebral infarction without residual deficits, to trigger an alert and involve the physician or initiate automated analysis and follow up back at the patient's clinic. Finally, in a still further embodiment, the circuitry 280 of the ICM 212 can accommodate patient-interfaceable components, including an external tactile feedback device (not shown) that wirelessly interfaces to the ICM 212 through the transceiver 285. A patient 210 can press the external tactile feedback device to mark events, such as a syncope episode, or to perform other functions. The circuitry 280 can also accommodate triggering an external buzzer 67, such as a speaker, magnetic resonator or piezoelectric buzzer, implemented as part of the external tactile feedback device or as a separate wirelessly-interfaceable component. The buzzer 67 can be used by the microcontroller 281 to indirectly output feedback to a patient 210, such as a low battery or other error condition or warning. Still other components, provided as either part of the circuitry 280 of the ICM 212 or as external wirelessly-interfaceable devices, are possible.


The ECG front end circuit 283 of the ICM 12 measures raw subcutaneous electrical signals using a driven reference signal, such as described in U.S. Pat. Nos. 9,700,227, 9,717,433, and 9,615,763, cited supra. The driven reference signal effectively reduces common mode noise, power supply noise and system noise, which is critical to preserving the characteristics of low amplitude cardiac action potentials, especially the P wave signals originating from the atria. The ECG front end circuit 283 is organized into a passive input filter stage, a unity gain voltage follower stage, a passive high pass filtering stage, a voltage amplification and active filtering stage, and an anti-aliasing passive filter stage, plus a reference generator. The passive input filter stage passively shifts the frequency response poles downward to counter the high electrode impedance from the patient on the signal lead and reference lead, which reduces high frequency noise. The unity gain voltage follower stage allows the circuit to accommodate a very high input impedance, so as not to disrupt the subcutaneous potentials or the filtering effect of the previous stage. The passive high pass filtering stage includes a high pass filter that removes baseline wander and any offset generated from the previous stage. As necessary, the voltage amplification and active filtering stage amplifies or de-amplifies (or allows to pass-through) the voltage of the input signal, while applying a low pass filter. The anti-aliasing passive filter stage provides an anti-aliasing low pass filter. The reference generator drives a driven reference signal containing power supply noise and system noise to the reference lead and is connected directly to the patient, thereby avoiding the thermal noise of the protection resistor that is included as part of the protection circuit.


While the invention has been particularly shown and described as referenced to the embodiments thereof, those skilled in the art will understand that the foregoing and other changes in form and detail may be made therein without departing from the spirit and scope.

Claims
  • 1. A cardiac monitoring system, comprising: an implantable housing comprised of a biocompatible material suitable for implantation within a living body;a pair of ECG sensing electrodes each provided as a wraparound electrode completely covering an end surface of the implantable housing between ventral and dorsal ends of the housing and a portion of each of two sides affixed to the end surface with one of the ECG sensing electrodes forming a superior pole on a proximal end of the implantable housing and the other ECG sensing electrode forming an inferior pole on a distal end of the implantable housing to capture P-wave signals that are generated during atrial activation;an electrode positioned on a ventral surface of the implantable housing and separated by a periphery from one of the wraparound electrodes, wherein the periphery is non-conductive and the electrode on the ventral surface and the wraparound electrode function separately or the periphery is conductive and the electrode on the ventral surface and the wraparound electrode function as a single electrode;electronic circuitry provided within the implantable housing comprising: a microcontroller; andan ECG front end circuit interfaced to the microcontroller and configured to capture cardiac action potentials of the P-wave signals sensed by the ECG sensing electrodes, andnon-volatile memory electrically interfaced with the microcontroller and operable to continuously store samples of the cardiac action potentials of the P-wave signals.
  • 2. A cardiac monitoring system in accordance claim 1, wherein one of the ECG sensing electrodes is dissimilar from the other ECG sensing electrode with respect to one or more of electrode size, shape, and surface area.
  • 3. A cardiac monitoring system in accordance with claim 1, wherein the electronic circuitry further comprises: a transceiver operable to wirelessly interface to an external device and perform at least one of provide the samples of the cardiac action potentials of the P-wave signals from the non-volatile memory to the external device and receive modular micro program control.
  • 4. A cardiac monitoring system in accordance with claim 3, wherein the microcontroller performs one or more steps comprising: monitor the cardiac action potentials of the P-wave signals sensed by the ECG sensing electrodes for arrhythmias of selected medical concern and wirelessly send an alert via the transceiver upon the occurrence of one of the arrhythmias of selected medical concern;execute heuristics to actively identify or narrow down a pattern or underlying cause of sporadic cardiac conditions and wirelessly send an alert via the transceiver upon the occurrence of one of the pattern and the underlying cause; andexecute programming tailored to the monitoring and medical diagnostic needs of at least one of a specific patient, patient group or general patient population of conditions or symptoms of medical concern and wirelessly send an alert via the transceiver upon the occurrence of one of the conditions or symptoms of medical concern.
  • 5. A cardiac monitoring system in accordance with claim 1, further comprising: a power up sequence comprising a check of operability and available capacity of a battery and the non-volatile memory, wherein the microcontroller is operable to execute the power up sequence upon the implantable housing being implanted into the body.
  • 6. A cardiac monitoring system in accordance with claim 5, wherein the power up sequence further comprises a confirmation of operation of the microcontroller.
  • 7. A cardiac monitoring system in accordance with claim 1, further comprising: at least one of the ECG sensing electrodes further provided to wraparound the ends of the implantable housing that are opposite one another.
  • 8. A cardiac monitoring system in accordance with claim 1, further comprising: a further ECG sensing electrode provided on the ventral surface of the implantable housing between the ECG sensing electrodes provided on the opposite ends of the implantable housing.
  • 9. A cardiac monitoring system in accordance with claim 1, further comprising: an actigraphy sensor electrically interfaced with the microcontroller and operable to sense actigraphy event occurrences based on movement of the sensor using an actigraphy event occurrence criteria and to send an interrupt signal to the micro-controller upon sensing each of the actigraphy event occurrences.
  • 10. A cardiac monitoring system in accordance with claim 1, the pair of the ECG sensing electrodes further comprising: an electrode shape selected from the group comprising circumferentially-shaped and asymmetrically-shaped electrodes.
  • 11. A cardiac monitoring system in accordance with claim 1, further comprising: a patient-interfaceable component selected from the group comprising an external tactile feedback device that wirelessly interfaces to a transceiver and an external buzzer implemented as part of the external tactile feedback device or as a separate wirelessly-interfaceable component.
  • 12. A cardiac monitoring system in accordance with claim 1, wherein the implantable housing comprises a hermetically sealed implantable housing defining a rectangular shape with rounded edges.
  • 13. A cardiac monitoring system in accordance with claim 1, wherein the implantable housing comprises an external surface having a length at least two times longer than a width of the external surface.
  • 14. A cardiac monitoring system in accordance with claim 13, wherein the width of each of two ends of the external surface are a same width.
  • 15. A cardiac monitoring system in accordance with claim 1, wherein the implantable housing is sized for vertical placement over at least a portion of a heart in the body.
  • 16. A cardiac monitoring system in accordance with claim 1, wherein the implantable housing comprises a hermetically sealed implantable housing defining a rectangular shape with rounded edges with a tapered extension that is terminated on the distal end with a further ECG sensing electrode.
  • 17. A cardiac monitoring system in accordance with claim 1, further comprising: a physiology sensor comprised within the implantable housing and electrically coupled to the electronic circuitry with the physiology sensor operable to sense physiology of the body; andthe non-volatile memory further operable to store samples of the physiology sensed by the physiology sensor.
  • 18. A cardiac monitoring system in accordance with claim 17, wherein the physiology sensor comprises one of an SpO2 sensor, a blood pressure sensor, a temperature sensor, a respiratory rate sensor, a glucose sensor, an air flow sensor, and a volumetric pressure sensor.
  • 19. A cardiac monitoring system in accordance with claim 1, further comprising: one or more memory storage locations comprised in the non-volatile memory in which samples of the ECG signals are stored,wherein, upon all of the memory storage locations being filled, the microcontroller is operable to overwrite the samples of the ECG signals stored in one of the memory storage locations to store the samples of the ECG signals acquired after the overwritten samples.
  • 20. A cardiac monitoring system in accordance with claim 1, further comprising: a battery comprised within the implantable housing and which powers the electronic circuitry.
CROSS-REFERENCE TO RELATED APPLICATIONS

This non-provisional patent application is a continuation of U.S. Pat. No. 10,624,551, issued Apr. 21, 2020, which is a continuation-in-part of U.S. Pat. No. 10,478,083, issued Nov. 19, 2019, which is continuation of U.S. Pat. No. 9,730,593, issued Aug. 15, 2017, and further claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent application, Ser. No. 61/882,403, filed Sep. 25, 2013, the filing dates of which are claimed and the disclosures of which are incorporated by reference; this present non-provisional patent application is also a continuation of U.S. Pat. No. 10,624,551, issued Apr. 21, 2020, which is a continuation-in-part of U.S. patent application Ser. No. 15/832,385, filed Dec. 5, 2017, pending, the disclosure of which is incorporated by reference.

US Referenced Citations (585)
Number Name Date Kind
3215136 Holter et al. Nov 1965 A
3569852 Berkovits Mar 1971 A
3602215 Parnell Aug 1971 A
3699948 Ota et al. Oct 1972 A
3718772 Sanctuary Feb 1973 A
3893453 Goldberg Jul 1975 A
4123785 Cherry et al. Oct 1978 A
4151513 Menken et al. Apr 1979 A
4328814 Arkans May 1982 A
4441500 Sessions et al. Apr 1984 A
4506678 Russell et al. Mar 1985 A
4532934 Kelen Aug 1985 A
4546342 Weaver et al. Oct 1985 A
4550502 Grayzel Nov 1985 A
4580572 Granek et al. Apr 1986 A
4635646 Gilles et al. Jan 1987 A
4653022 Koro Mar 1987 A
4716903 Hansen Jan 1988 A
4788983 Brink et al. Dec 1988 A
4809705 Ascher Mar 1989 A
4915656 Alferness Apr 1990 A
5007429 Treatch et al. Apr 1991 A
5025794 Albert et al. Jun 1991 A
5107480 Naus Apr 1992 A
5168876 Quedens et al. Dec 1992 A
5215098 Steinhaus Jun 1993 A
5231990 Gauglitz Aug 1993 A
D341423 Bible Nov 1993 S
5263481 Axelgaard Nov 1993 A
5265579 Ferrari Nov 1993 A
5312446 Holschbach et al. May 1994 A
5314453 Jeutter May 1994 A
5331966 Bennett et al. Jul 1994 A
5333615 Craelius et al. Aug 1994 A
5341806 Gadsby et al. Aug 1994 A
5348008 Bornn et al. Sep 1994 A
5355891 Wateridge et al. Oct 1994 A
5365934 Leon et al. Nov 1994 A
5365935 Righter et al. Nov 1994 A
5392784 Gudaitis Feb 1995 A
D357069 Plahn et al. Apr 1995 S
5402780 Faasse, Jr. Apr 1995 A
5402884 Gilman et al. Apr 1995 A
5450845 Axelgaard Sep 1995 A
5451876 Sendford et al. Sep 1995 A
5458141 Neil Oct 1995 A
5473537 Glazer et al. Dec 1995 A
5479922 Reichl Jan 1996 A
5483969 Testerman et al. Jan 1996 A
5511553 Segalowitz Apr 1996 A
5540733 Testerman et al. Jul 1996 A
5546952 Erickson Aug 1996 A
5549655 Erickson Aug 1996 A
5579919 Gilman et al. Dec 1996 A
5582181 Ruess Dec 1996 A
D377983 Sabri et al. Feb 1997 S
5601089 Bledsoe et al. Feb 1997 A
5623935 Faisandier Apr 1997 A
5682901 Kamen Nov 1997 A
5697955 Stolte Dec 1997 A
5724967 Venkatachalam Mar 1998 A
5749902 Olsen et al. May 1998 A
5788633 Mahoney Aug 1998 A
5817151 Olsen et al. Oct 1998 A
5819741 Karlsson et al. Oct 1998 A
5850920 Gilman et al. Dec 1998 A
5860918 Schradi et al. Jan 1999 A
D407159 Roberg Mar 1999 S
5876351 Rohde Mar 1999 A
5906583 Rogel May 1999 A
5957857 Hartley Jul 1999 A
5951598 Bishay et al. Sep 1999 A
5956013 Raj et al. Sep 1999 A
5984102 Tay Nov 1999 A
5987352 Klein et al. Nov 1999 A
6032064 Devlin et al. Feb 2000 A
6038469 Karlsson et al. Mar 2000 A
6101413 Olsen et al. Aug 2000 A
6115638 Groenke Sep 2000 A
6117077 Del Mar et al. Sep 2000 A
6134479 Brewer et al. Oct 2000 A
6148233 Owen et al. Nov 2000 A
6149602 Arcelus Nov 2000 A
6149781 Forand Nov 2000 A
6185452 Schulman et al. Feb 2001 B1
6188407 Smith et al. Feb 2001 B1
D443063 Pisani et al. May 2001 S
6245025 Torok et al. Jun 2001 B1
6246330 Nielsen Jun 2001 B1
6249696 Olson et al. Jun 2001 B1
D445507 Pisani et al. Jul 2001 S
6269267 Bardy et al. Jul 2001 B1
6272385 Bishay et al. Aug 2001 B1
6298255 Cordero et al. Oct 2001 B1
6301502 Owen et al. Oct 2001 B1
6304773 Taylor et al. Oct 2001 B1
6304780 Owen et al. Oct 2001 B1
6304783 Lyster et al. Oct 2001 B1
6374138 Owen et al. Apr 2002 B1
6381482 Jayaraman et al. Apr 2002 B1
6416471 Kumar et al. Jul 2002 B1
6418342 Owen et al. Jul 2002 B1
6424860 Karlsson et al. Jul 2002 B1
6427083 Owen et al. Jul 2002 B1
6427085 Boon et al. Jul 2002 B1
6434410 Cordero Aug 2002 B1
6454708 Ferguson et al. Sep 2002 B1
6456256 Amundson et al. Sep 2002 B1
6456872 Faisandier Sep 2002 B1
6463320 Xue et al. Oct 2002 B1
6546285 Owen et al. Apr 2003 B1
6605046 Del Mar Aug 2003 B1
6607485 Bardy Aug 2003 B2
6611705 Hopman et al. Aug 2003 B2
6671545 Fincke Dec 2003 B2
6671547 Lyster et al. Dec 2003 B2
6694186 Bardy Feb 2004 B2
6704595 Bardy Mar 2004 B2
6705991 Bardy Mar 2004 B2
6719701 Lade Apr 2004 B2
6754523 Toole Jun 2004 B2
6782293 Dupelle et al. Aug 2004 B2
6856832 Matsumura Feb 2005 B1
6860897 Bardy Mar 2005 B2
6866629 Bardy Mar 2005 B2
6887201 Bardy May 2005 B2
6893397 Bardy May 2005 B2
6895261 Palamides May 2005 B1
6904312 Bardy Jun 2005 B2
6908431 Bardy Jun 2005 B2
6913577 Bardy Jul 2005 B2
6944498 Owen et al. Sep 2005 B2
6960167 Bardy Nov 2005 B2
6970731 Jayaraman et al. Nov 2005 B1
6978169 Guerra Dec 2005 B1
6993377 Flick et al. Jan 2006 B2
7020508 Stivoric et al. Mar 2006 B2
7027864 Snyder et al. Apr 2006 B2
7052472 Miller et al. May 2006 B1
7065401 Worden Jun 2006 B2
7085601 Bardy et al. Aug 2006 B1
7104955 Bardy Sep 2006 B2
7134996 Bardy Nov 2006 B2
7137389 Berthon-Jones Nov 2006 B2
7147600 Bardy Dec 2006 B2
7215991 Besson et al. May 2007 B2
7248916 Bardy Jul 2007 B2
7257438 Kinast Aug 2007 B2
7277752 Matos Oct 2007 B2
7294108 Bornzin et al. Nov 2007 B1
D558882 Brady Jan 2008 S
7328061 Rowlandson et al. Feb 2008 B2
7412395 Rowlandson et al. Aug 2008 B2
7429938 Corndorf Sep 2008 B1
7552031 Vock et al. Jun 2009 B2
D606656 Kobayashi et al. Dec 2009 S
7672714 Kuo et al. Mar 2010 B2
7706870 Shieh et al. Apr 2010 B2
7756721 Falchuk et al. Jul 2010 B1
7787943 McDonough Aug 2010 B2
7874993 Bardy Jan 2011 B2
7881785 Nassif et al. Feb 2011 B2
D639437 Bishay et al. Jun 2011 S
7959574 Bardy Jun 2011 B2
8108035 Bharmi Jan 2012 B1
8116841 Bly et al. Feb 2012 B2
8135459 Bardy et al. Mar 2012 B2
8172761 Rulkov et al. May 2012 B1
8180425 Selvitelli et al. May 2012 B2
8200320 Kovacs Jun 2012 B2
8231539 Bardy Jul 2012 B2
8231540 Bardy Jul 2012 B2
8239012 Felix et al. Aug 2012 B2
8249686 Libbus et al. Aug 2012 B2
8260414 Nassif et al. Sep 2012 B2
8266008 Siegel et al. Sep 2012 B1
8277378 Bardy Oct 2012 B2
8285356 Bly et al. Oct 2012 B2
8285370 Felix et al. Oct 2012 B2
8308650 Bardy Nov 2012 B2
8366629 Bardy Feb 2013 B2
8374688 Libbus et al. Feb 2013 B2
8412317 Mazar Apr 2013 B2
8460189 Libbus et al. Jun 2013 B2
8473047 Chakravarthy et al. Jun 2013 B2
8478418 Fahey Jul 2013 B2
8538503 Kumar et al. Sep 2013 B2
8545416 Kayyali et al. Oct 2013 B1
8554311 Warner et al. Oct 2013 B2
8560046 Kumar et al. Oct 2013 B2
8591430 Amurthur et al. Nov 2013 B2
8594763 Bibian et al. Nov 2013 B1
8600486 Kaib et al. Dec 2013 B2
8613708 Bishay et al. Dec 2013 B2
8613709 Bishay et al. Dec 2013 B2
8620418 Kuppuraj et al. Dec 2013 B1
8626277 Felix et al. Jan 2014 B2
8628020 Beck Jan 2014 B2
8668653 Nagata et al. Mar 2014 B2
8684925 Manicka et al. Apr 2014 B2
8688190 Libbus et al. Apr 2014 B2
8718752 Libbus et al. May 2014 B2
8744561 Fahey Jun 2014 B2
8774932 Fahey Jul 2014 B2
8790257 Libbus et al. Jul 2014 B2
8790259 Katra et al. Jul 2014 B2
8795174 Manicka et al. Aug 2014 B2
8798729 Kaib et al. Aug 2014 B2
8798734 Kuppuraj et al. Aug 2014 B2
8818478 Scheffler et al. Aug 2014 B2
8818481 Bly et al. Aug 2014 B2
8823490 Libbus et al. Sep 2014 B2
8858432 Robertson et al. Oct 2014 B2
8938287 Felix et al. Jan 2015 B2
8948935 Peeters Feb 2015 B1
8965492 Baker et al. Feb 2015 B2
9066664 Karjalainen Jun 2015 B2
9135608 Herlitz Sep 2015 B2
9155484 Baker et al. Oct 2015 B2
9204813 Kaib et al. Dec 2015 B2
9241649 Kumar et al. Jan 2016 B2
9259154 Miller et al. Feb 2016 B2
9277864 Yang et al. Mar 2016 B2
9339202 Brockway et al. May 2016 B2
9375179 Schultz et al. Jun 2016 B2
9414786 Brockway et al. Aug 2016 B1
9439566 Arne et al. Sep 2016 B2
9597004 Hughes et al. Mar 2017 B2
9603542 Veen et al. Mar 2017 B2
9700222 Quinlan et al. Jul 2017 B2
9770182 Bly et al. Sep 2017 B2
10034614 Edie et al. Jul 2018 B2
10045708 Dusan Aug 2018 B2
10049182 Chefles et al. Aug 2018 B2
20010051766 Gazdzinski Dec 2001 A1
20020013538 Teller Jan 2002 A1
20020013717 Ando et al. Jan 2002 A1
20020016798 Sakai Feb 2002 A1
20020082867 MacCarter et al. Jun 2002 A1
20020103422 Harder et al. Aug 2002 A1
20020109621 Khair et al. Aug 2002 A1
20020120310 Linden et al. Aug 2002 A1
20020128686 Minogue et al. Sep 2002 A1
20020184055 Naghavi et al. Dec 2002 A1
20020193668 Munneke Dec 2002 A1
20030004547 Owen et al. Jan 2003 A1
20030028811 Walker et al. Feb 2003 A1
20030073916 Yonce Apr 2003 A1
20030083559 Thompson May 2003 A1
20030097078 Maeda May 2003 A1
20030139785 Riff et al. Jul 2003 A1
20030149349 Jensen Aug 2003 A1
20030174881 Simard et al. Sep 2003 A1
20030176802 Galen et al. Sep 2003 A1
20030211797 Hill et al. Nov 2003 A1
20040008123 Carrender Jan 2004 A1
20040019288 Kinast Jan 2004 A1
20040034284 Aversano et al. Feb 2004 A1
20040049120 Cao et al. Mar 2004 A1
20040049132 Barron et al. Mar 2004 A1
20040073127 Istvan et al. Apr 2004 A1
20040087836 Green et al. May 2004 A1
20040088019 Rueter et al. May 2004 A1
20040093192 Hasson et al. May 2004 A1
20040116784 Gavish Jun 2004 A1
20040148194 Wellons et al. Jul 2004 A1
20040163034 Colbath et al. Aug 2004 A1
20040167416 Lee Aug 2004 A1
20040207530 Nielsen Oct 2004 A1
20040210165 Marmaropoulos et al. Oct 2004 A1
20040236202 Burton Nov 2004 A1
20040243435 Williams Dec 2004 A1
20040256453 Lammle Dec 2004 A1
20040260188 Syed et al. Dec 2004 A1
20040260192 Yamamoto Dec 2004 A1
20050010139 Aminian et al. Jan 2005 A1
20050043640 Chang Feb 2005 A1
20050058701 Gross et al. Mar 2005 A1
20050096717 Bishay et al. May 2005 A1
20050101875 Semler et al. May 2005 A1
20050108055 Ott et al. May 2005 A1
20050113661 Nazeri May 2005 A1
20050137485 Cao et al. Jun 2005 A1
20050151640 Hastings Jul 2005 A1
20050154267 Bardy Jul 2005 A1
20050154294 Uchiyama et al. Jul 2005 A1
20050182308 Bardy Aug 2005 A1
20050182309 Bardy Aug 2005 A1
20050215918 Frantz et al. Sep 2005 A1
20050222513 Hadley et al. Oct 2005 A1
20050228243 Bardy Oct 2005 A1
20050245839 Stivoric et al. Nov 2005 A1
20050261564 Ryu et al. Nov 2005 A1
20050275416 Hervieux et al. Dec 2005 A1
20060025696 Kurzweil et al. Feb 2006 A1
20060025824 Freeman et al. Feb 2006 A1
20060030767 Lang et al. Feb 2006 A1
20060030781 Shennib Feb 2006 A1
20060030904 Quiles Feb 2006 A1
20060041201 Behbehani et al. Feb 2006 A1
20060084883 Linker Apr 2006 A1
20060100530 Kliot et al. May 2006 A1
20060111642 Baura et al. May 2006 A1
20060111943 Wu May 2006 A1
20060122469 Martel Jun 2006 A1
20060124193 Orr et al. Jun 2006 A1
20060167502 Haefner Jul 2006 A1
20060224072 Shennib Oct 2006 A1
20060229522 Barr Oct 2006 A1
20060235320 Tan et al. Oct 2006 A1
20060253006 Bardy Nov 2006 A1
20060264730 Stivoric et al. Nov 2006 A1
20060264767 Shennib Nov 2006 A1
20070003115 Patton et al. Jan 2007 A1
20070038057 Nam et al. Feb 2007 A1
20070050209 Yered Mar 2007 A1
20070078324 Wijisiriwardana Apr 2007 A1
20070078354 Holland Apr 2007 A1
20070088406 Bennett et al. Apr 2007 A1
20070088419 Fiorina et al. Apr 2007 A1
20070089800 Sharma Apr 2007 A1
20070093719 Nichols, Jr. et al. Apr 2007 A1
20070100248 Van Dam et al. May 2007 A1
20070100667 Bardy May 2007 A1
20070123801 Goldberger et al. May 2007 A1
20070131595 Jansson et al. Jun 2007 A1
20070136091 McTaggart Jun 2007 A1
20070142722 Chang Jun 2007 A1
20070179357 Bardy Aug 2007 A1
20070185390 Perkins et al. Aug 2007 A1
20070203415 Bardy Aug 2007 A1
20070203423 Bardy Aug 2007 A1
20070208232 Kovacs Sep 2007 A1
20070208233 Kovacs Sep 2007 A1
20070208266 Hadley Sep 2007 A1
20070225611 Kumar et al. Sep 2007 A1
20070233198 Ghanem et al. Oct 2007 A1
20070244405 Xue et al. Oct 2007 A1
20070249946 Kumar et al. Oct 2007 A1
20070255153 Kumar et al. Nov 2007 A1
20070265510 Bardy Nov 2007 A1
20070270678 Fadem Nov 2007 A1
20070276270 Tran Nov 2007 A1
20070276275 Proctor et al. Nov 2007 A1
20070293738 Bardy Dec 2007 A1
20070293739 Bardy Dec 2007 A1
20070293740 Bardy Dec 2007 A1
20070293741 Bardy Dec 2007 A1
20070293772 Bardy Dec 2007 A1
20070299325 Farrell et al. Dec 2007 A1
20070299617 Willis Dec 2007 A1
20080027337 Dugan Jan 2008 A1
20080027339 Nagai et al. Jan 2008 A1
20080051668 Bardy Feb 2008 A1
20080058661 Bardy Mar 2008 A1
20080143080 Burr Mar 2008 A1
20080088467 Al-Ali et al. Apr 2008 A1
20080091089 Guillory et al. Apr 2008 A1
20080091097 Linti et al. Apr 2008 A1
20080108890 Teng et al. May 2008 A1
20080114232 Gazit May 2008 A1
20080139953 Baker et al. Jun 2008 A1
20080177168 Callahan et al. Jul 2008 A1
20080194927 KenKnight et al. Aug 2008 A1
20080208009 Shklarski Aug 2008 A1
20080208014 KenKnight et al. Aug 2008 A1
20080243012 Fujihashi et al. Oct 2008 A1
20080284599 Zdeblick et al. Nov 2008 A1
20080288026 Cross et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080306359 Zdeblick et al. Dec 2008 A1
20080309481 Tanaka et al. Dec 2008 A1
20080312522 Rowlandson et al. Dec 2008 A1
20090009342 Karjalainen Jan 2009 A1
20090012412 Wiesel Jan 2009 A1
20090012979 Bateni et al. Jan 2009 A1
20090054737 Magar et al. Feb 2009 A1
20090054952 Glukhovsky et al. Feb 2009 A1
20090062670 Sterling Mar 2009 A1
20090062897 Axelgaard Mar 2009 A1
20090069867 KenKnight et al. Mar 2009 A1
20090073991 Landrum et al. Mar 2009 A1
20090076336 Mazar et al. Mar 2009 A1
20090076341 James et al. Mar 2009 A1
20090076342 Amurthur et al. Mar 2009 A1
20090076343 James et al. Mar 2009 A1
20090076346 James et al. Mar 2009 A1
20090076349 Libbus et al. Mar 2009 A1
20090076397 Libbus et al. Mar 2009 A1
20090076401 Mazar et al. Mar 2009 A1
20090076559 Libbus et al. Mar 2009 A1
20090076364 Libbus et al. Apr 2009 A1
20090088652 Tremblay Apr 2009 A1
20090093687 Telfort et al. Apr 2009 A1
20090112116 Lee et al. Apr 2009 A1
20090131759 Sims et al. May 2009 A1
20090133047 Lee et al. May 2009 A1
20090156908 Belalcazar et al. Jun 2009 A1
20090182204 Semler et al. Jul 2009 A1
20090216132 Orbach Aug 2009 A1
20090270708 Shen et al. Oct 2009 A1
20090270747 Van Dam et al. Oct 2009 A1
20090292194 Libbus et al. Nov 2009 A1
20090327715 Smith et al. Dec 2009 A1
20100007413 Herleikson et al. Jan 2010 A1
20100022897 Parker et al. Jan 2010 A1
20100056877 Fein et al. Mar 2010 A1
20100056881 Libbus et al. Mar 2010 A1
20100076517 Imran Mar 2010 A1
20100081913 Cross et al. Apr 2010 A1
20100137694 Irazoqui et al. Jun 2010 A1
20100174229 Hsu et al. Jul 2010 A1
20100177100 Carnes et al. Jul 2010 A1
20100185063 Bardy Jul 2010 A1
20100185076 Jeong et al. Jul 2010 A1
20100191154 Berger et al. Jul 2010 A1
20100191310 Bly Jul 2010 A1
20100223020 Goetz Sep 2010 A1
20100234697 Walter et al. Sep 2010 A1
20100234715 Shin et al. Sep 2010 A1
20100234716 Engel Sep 2010 A1
20100268103 McNamara et al. Oct 2010 A1
20100280366 Arne et al. Nov 2010 A1
20100298720 Potkay Nov 2010 A1
20100312188 Robertson et al. Dec 2010 A1
20100317957 Lee et al. Dec 2010 A1
20100324384 Moon et al. Dec 2010 A1
20100324405 Niemi et al. Dec 2010 A1
20110021937 Hugh et al. Jan 2011 A1
20110054286 Crosby et al. Mar 2011 A1
20110060215 Tupin et al. Mar 2011 A1
20110066041 Pandia et al. Mar 2011 A1
20110077497 Oster et al. Mar 2011 A1
20110082842 Groseclose, Jr. et al. Apr 2011 A1
20110105861 Derchak et al. May 2011 A1
20110112379 Li et al. May 2011 A1
20110144470 Mazar et al. Jun 2011 A1
20110160548 Forster Jun 2011 A1
20110160601 Wang et al. Jun 2011 A1
20110208076 Fong et al. Aug 2011 A1
20110224564 Moon et al. Sep 2011 A1
20110237922 Parker, III et al. Sep 2011 A1
20110237924 McGusty et al. Sep 2011 A1
20110245699 Snell et al. Oct 2011 A1
20110245711 Katra et al. Oct 2011 A1
20110288605 Kaib et al. Nov 2011 A1
20110313305 Rantala Dec 2011 A1
20120003933 Baker et al. Jan 2012 A1
20120029300 Paquet Feb 2012 A1
20120029306 Paquet et al. Feb 2012 A1
20120029309 Paquest et al. Feb 2012 A1
20120029314 Paquet et al. Feb 2012 A1
20120029315 Raptis et al. Feb 2012 A1
20120029316 Raptis et al. Feb 2012 A1
20120035432 Katra et al. Feb 2012 A1
20120059668 Baldock et al. Mar 2012 A1
20120078127 McDonald et al. Mar 2012 A1
20120088998 Bardy et al. Apr 2012 A1
20120088999 Bishay et al. Apr 2012 A1
20120089000 Bishay et al. Apr 2012 A1
20120089001 Bishay et al. Apr 2012 A1
20120089037 Bishay et al. Apr 2012 A1
20120089412 Bishay et al. Apr 2012 A1
20120089417 Bardy et al. Apr 2012 A1
20120095352 Tran Apr 2012 A1
20120101358 Boettcher et al. Apr 2012 A1
20120101396 Solosko et al. Apr 2012 A1
20120108993 Gordon et al. May 2012 A1
20120165645 Russel et al. Jun 2012 A1
20120306662 Vosch et al. Jun 2012 A1
20120172695 Ko et al. Jul 2012 A1
20120179665 Baarman et al. Jul 2012 A1
20120184207 Gaines Jul 2012 A1
20120220835 Chung Aug 2012 A1
20120232929 Experton Sep 2012 A1
20120238910 Nordstrom Sep 2012 A1
20120253847 Dell'Anno et al. Oct 2012 A1
20120265080 Yu et al. Oct 2012 A1
20120265738 Beckmann et al. Oct 2012 A1
20120302906 Felix et al. Nov 2012 A1
20120330126 Hoppe et al. Dec 2012 A1
20130041272 Javier et al. Feb 2013 A1
20130077263 Oleson et al. Mar 2013 A1
20130079611 Besko Mar 2013 A1
20130079618 Sandmore et al. Mar 2013 A1
20130085347 Manicka et al. Apr 2013 A1
20130085403 Gunderson et al. Apr 2013 A1
20130087609 Nichol et al. Apr 2013 A1
20130096395 Katra et al. Apr 2013 A1
20130116533 Lian et al. May 2013 A1
20130123651 Bardy May 2013 A1
20130124891 Donaldson May 2013 A1
20130131530 Brockway et al. May 2013 A1
20130158361 Bardy Jun 2013 A1
20130172763 Wheeler Jul 2013 A1
20130197380 Oral et al. Aug 2013 A1
20130225963 Kodandaramaiah et al. Aug 2013 A1
20130225966 Barber et al. Aug 2013 A1
20130231947 Shusterman Sep 2013 A1
20130243105 Lei et al. Sep 2013 A1
20130274565 Langer et al. Oct 2013 A1
20130274584 Finlay et al. Oct 2013 A1
20130275158 Fahey Oct 2013 A1
20130324809 Lisogurski et al. Dec 2013 A1
20130324855 Lisogurski et al. Dec 2013 A1
20130324856 Lisogurski et al. Dec 2013 A1
20130325081 Karst et al. Dec 2013 A1
20130325359 Jarverud et al. Dec 2013 A1
20130331665 Libbus et al. Dec 2013 A1
20130338448 Libbus et al. Dec 2013 A1
20130338472 Barber et al. Dec 2013 A1
20140002234 Alwan Jan 2014 A1
20140005502 Klap et al. Jan 2014 A1
20140012154 Mazar et al. Jan 2014 A1
20140031663 Gallego Jan 2014 A1
20140056452 Moss et al. Feb 2014 A1
20140088399 Lian et al. Mar 2014 A1
20140107509 Banet et al. Apr 2014 A1
20140121557 Gannon et al. May 2014 A1
20140140359 Kalevo et al. May 2014 A1
20140148718 Stickney et al. May 2014 A1
20140180027 Buller Jun 2014 A1
20140189928 Oleson et al. Jul 2014 A1
20140194760 Albert Jul 2014 A1
20140206977 Bahney et al. Jul 2014 A1
20140213937 Bianchi et al. Jul 2014 A1
20140214134 Peterson Jul 2014 A1
20140215246 Lee et al. Jul 2014 A1
20140249852 Proud Sep 2014 A1
20140296651 Stone Oct 2014 A1
20140297310 Collins Oct 2014 A1
20140318699 Longinotti-Buitoni et al. Oct 2014 A1
20140330147 Ousdigian et al. Nov 2014 A1
20140343390 Berzowska et al. Nov 2014 A1
20140358193 Lyons et al. Dec 2014 A1
20140364756 Brockway et al. Dec 2014 A1
20150018660 Thomson et al. Jan 2015 A1
20150048836 Guthrie et al. Feb 2015 A1
20150051472 Wang et al. Feb 2015 A1
20150065842 Lee et al. Mar 2015 A1
20150094558 Russell Apr 2015 A1
20150142090 Duijsens et al. May 2015 A1
20150164349 Gopalakrishnan et al. Jun 2015 A1
20150165211 Naqvi et al. Jun 2015 A1
20150177175 Elder et al. Jun 2015 A1
20150202351 Kaplan et al. Jul 2015 A1
20150250422 Bay Sep 2015 A1
20150257670 Ortega et al. Sep 2015 A1
20150305676 Shoshani Nov 2015 A1
20150324690 Chilimbi et al. Nov 2015 A1
20150335285 Poon et al. Nov 2015 A1
20150359489 Baudenbacher et al. Dec 2015 A1
20160135746 Kumar et al. May 2016 A1
20160144190 Cao et al. May 2016 A1
20160144192 Sanghera et al. May 2016 A1
20160150982 Roy Jun 2016 A1
20160196479 Chertok et al. Jul 2016 A1
20160217369 Annapureddy et al. Jul 2016 A1
20160217691 Kadobayashi et al. Jul 2016 A1
20160235318 Sarkar Aug 2016 A1
20170056650 Cohen et al. Mar 2017 A1
20170112399 Brisben et al. Apr 2017 A1
20170112401 Rapin et al. Apr 2017 A1
20170127964 Moorman May 2017 A1
20170156592 Fu Jun 2017 A1
20170032221 Wu et al. Jul 2017 A1
20170281032 Weinberg et al. Oct 2017 A1
20170281033 Higgins et al. Oct 2017 A1
20170354365 Zhou Dec 2017 A1
20170366921 Pflugh et al. Dec 2017 A1
20180020931 Shusterman Jan 2018 A1
20180042552 Li et al. Feb 2018 A1
20180078771 Koop et al. Mar 2018 A1
20180116537 Sullivan et al. May 2018 A1
20180129893 Son et al. May 2018 A1
20180192965 Rose et al. Jul 2018 A1
20180264258 Cheng et al. Sep 2018 A1
20180333058 Coulon et al. Nov 2018 A1
20190021671 Kumar et al. Jan 2019 A1
20190046038 Weinstein et al. Feb 2019 A1
20190059763 Shakur et al. Feb 2019 A1
20190069815 Burnes et al. Mar 2019 A1
20190117068 Thomson et al. Apr 2019 A1
20190336032 Gill et al. Nov 2019 A1
20200038671 Schulhauser et al. Feb 2020 A1
Foreign Referenced Citations (39)
Number Date Country
19955211 May 2001 DE
1859833 Nov 2007 EP
2438851 Apr 2012 EP
2438852 Apr 2012 EP
2465415 Jun 2012 EP
2589333 May 2013 EP
H06319711 Nov 1994 JP
H11188015 Jul 1999 JP
2004129788 Apr 2004 JP
2007082938 Apr 2007 JP
2009219554 Oct 2009 JP
199852463 Nov 1998 WO
0078213 Dec 2000 WO
2003032192 Apr 2003 WO
2006009767 Jan 2006 WO
2006014806 Feb 2006 WO
2007066270 Jun 2007 WO
2007092543 Aug 2007 WO
2008010216 Jan 2008 WO
2008057884 May 2008 WO
2008092098 Jul 2008 WO
2009036306 Mar 2009 WO
2009036313 Mar 2009 WO
2009036327 Mar 2009 WO
2009112976 Sep 2009 WO
2009112978 Sep 2009 WO
2009112979 Sep 2009 WO
2009142975 Nov 2009 WO
2010066507 Jun 2010 WO
2010105045 Jun 2010 WO
2010104952 Sep 2010 WO
2011047207 Apr 2011 WO
2012040487 Mar 2012 WO
2012112407 Aug 2012 WO
2012140559 Oct 2012 WO
2012146957 Nov 2012 WO
2017072250 May 2017 WO
2019030746 Feb 2019 WO
2019073288 Apr 2019 WO
Non-Patent Literature Citations (71)
Entry
Pranav Rajpurkar et al. “Cardiologist-Level Arrhythmia Detection with Convolutional Neural Networks,”arxiv.org, Cornell University Library, 201 Olin Library Cornell University Ithaca, NY 14853, Jul. 6, 2017 (Jul. 6, 2017), XP080774895.
Pourbabaee Bahareh et al. “Feature Learning with Deep Convolutional Neural Networks for Screening Patients with Paroxysmal Atrial Fibrillation,” 2016 Neural Networks (IJCNN), 2016 International Joint Conference on Neural Networks (IJCNN), IEEE, Jul. 24, 2016 (Jul. 24, 2016), pp. 5057-5064, XP032992832, DOI: 10.1109/IJCNN.2016.7727866.
Xiong Zhaohan et al. “Robust ECG Signal Classification for Detection of Atrial Fibrillation Using a Novel Neural Network,” 2017 Computing in Cardiology (CinC), CCAL, Sep. 24, 2017 (Sep. 24, 2017), pp. 1-4, XP033343575, DOI: 10.22489/CinC.2017.066-138.
Wallot et al., “Using Complexity Metrics With R-R Intervals And BPM Heart Rate Measures,” Frontiers in Physiology, vol. 4, Article 211, pp. 1-8, Aug. 13, 2013. 2013.
https://fccid.io/LF524950/User-Manual/User-Manual-1944573 © Medtronic, Inc. 2012.
https://en wikipedia.org/wiki/Convolutional_neural_network#Receptive_fields_in_the_visual_cortex (Year: 2017).
Dan Sapoznikov et al., “Comparison of Different Methodologies of Heart Rate Variability Analysis,” Department of Cardiology, Hadassah University Hospital, P.O.B. 12000, Ein Kerem, Jerusalem 91120, Israel (1993).
Jeffrey J. Goldberger, MD, FHRS, et al., “Comparison of the Physiologic and Prognostic Implications of the Heart Rate Versus the RR Interval,” Heart Rhythm, Elseview, US, vol. 11, No. 11, Jul. 30, 2014 (Jul. 30, 2014), pp. 1925-1933, XP029082764, ISSN: 1547-5271, DOI: 10.1016/J.HRTHM.2014.07.037 (2014).
Giuseppe Ciconte et al., “The Role Of Implantable Cardiac Monitors In Artial Fibrillation Management,” Journal For Atrial Finrillation: JAFIB, vol. 10, No. 2, Aug. 31, 2017 (Aug. 31, 2017), XPO55732155, ISSN: 1941-6911, DOI: 10.4022/jafib. 1590. Aug. 31, 2017.
BioMonitor 2 Cardiac Monitor With Fast Insert Tools BIOTRONIK Home Monitoring, BioMonitor 2—technical manual, Jul. 6, 2017 (Jul. 6, 2017), pp. 1-29, XPO55732157, [retrieved on Sep. 18, 2020].
“RevealLINQ Product Specifications,” Dec. 1, 2017 (Dec. 1, 2017), XPO55732158, [retrieved on Sep. 18, 2020].
Helmut Purerfellner et al.: “Miniaturized Reveal LINQ insertable cardiac monitoring system: First-in-human experience,” Heart Rhythm, vol. 12. No. 6, Jun. 1, 2015 (Jun. 1, 2015), pp. 1113-1119, XP055732303, US ISSN: 1547-5271, DOI: 10.1016/j.hrthm.2015.02.030.
15 Of The Hottest Wearable Gadgets, URL <http://thehottestgadgets.com/2008/09/the-15-hottest-wearable-gadgets-001253> (Web page cached on Sep. 27, 2008).
Alivecor, URL <http://www.businesswire.com/news/home/20121203005545/en/AliveCor%E2%80%99s-Heart-Monitor-iPhone-Receives-FDA-Clearance#.U7rtq7FVTyF> (Dec. 3, 2012).
Bharadwaj et al., Techniques for Accurate ECG signal processing, EE Times, URL <www.eetimes.com/document.asp?doc_id=1278571 > (Feb. 14, 2011).
Chen et al. “Monitoring Body Temperature of Newborn Infants At Neonatal Intensive Care Units Using Wearable Sensors,” BodyNets2010, Corfu Island, Greece. Sep. 10-12, 1210.
Epstein, Andrew E. et al.; ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. J. Am. Coll. Cardiol. 2008; 51; el-e62, 66 Pgs.
Fitbit Tracker, URL <http://www.fitbit.com/> (Web page cached on Sep. 10, 2008.).
Smith, Jawbone Up, URL <http://www.businessinsider.com/fitbit-flex-vs-jawbone-up-2013-5?op=1> (Jun. 1, 2013).
Kligfield, Paul et al., Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part I. J.Am.Coll. Cardiol; 2007; 49; 1109-27, 75 Pgs.
Lauren Gravitz, “When Your Diet Needs A Band-Aid,” Technology Review, MIT. (May 1, 2009).
Lieberman, Jonathan, “How Telemedicine Is Aiding Prompt ECG Diagnosis In Primary Care,” British Journal of Community Nursing, vol. 13, No. 3, Mar. 1, 2008 (Mar. 1, 2008), pp. 123-126, XP009155082, ISSN: 1462-4753.
McManus et al., “A Novel Application for the Detection of an Irregular Pulse using an iPhone 4S in Patients with Atrial Fibrillation,” vol. 10(3), pp. 315-319 (Mar. 2013.).
Nike+ Fuel Band, URL <http://www.nike.com/us/en_us/c/nikeplus-fuelband> (Web page cached on Jan. 11, 2013.).
P. Libby et al.,“Braunwald's Heart Disease—A Textbook of Cardiovascular Medicine,” Chs. 11, pp. 125-148 and 12, pp. 149-193 (8th ed. 2008), American Heart Association.
Initial hands-on with Polar Loop activity tracker, URL <http://www.dcrainmaker.com/2013/09/polar-loop-firstlook.html> (Sep. 17, 2013).
Seifert, Dan, Samsung dives into fitness wearable with the Gear Fit/ The Verge, URL <http://www.theverge.com/2014/2/24/5440310/samsung-dives-into-fitness-wearables-with-the-gear-fit> (Feb. 24, 2014).
Soper, Taylor, Samsung's new Galaxy S5 flagship phone has fingerprint reader, heart rate monitor, URL <http://www.geekwire.com/2014/samsung-galaxy-s5-fingerprint> (Feb. 24, 2014).
Dolcourt, See the Samsung Galaxy S5's Heart rate monitor in action, URL <http://www.cnet.com/news/see-the-samsung-galaxy-s5s-heart-rate-monitor-in-action> (Feb. 25, 2014).
Sittig et al., “A Computer-Based Outpatient Clinical Referral System,” International Journal of Medical Informatics, Shannon, IR, vol. 55, No. 2, Aug. 1, 1999, pp. 149-158, XO004262434, ISSN: 1386-5056(99)00027-1.
Sleepview, URL <http://www.clevemed.com/sleepview/overview.shtml> (Web page cached on Sep. 4, 2013.).
Actigraphy/ Circadian Rhythm SOMNOwatch, URL <http://www.somnomedics.eu/news-events/publications/somnowatchtm.html> (Web page cached on Jan. 23, 2010).
Zio Event Card, URL <http://www.irhythmtech.com/zio-solution/zio-event/> (Web page cached on Mar. 11, 2013.).
Zio Patch System, URL <http://www.irhythmtech.com/zio-solution/zio-system/index.html> (Web page cached on Sep. 8, 2013.).
Saadi et al. “Heart Rhythm Analysis Using ECG Recorded With A Novel Sternum Based Patch Technology—A Pilot Study.” Cardio technix 2013—Proceedings of the International Congress on Cardiovascular Technologies, Sep. 20, 2013.
Anonymous. “Omegawave Launches Consumer App 2.0 in U.S. Endurance Sportswire—Endurance Sportswire.” Jul. 11, 2013. URL:http://endurancesportswire.com/omegawave-launches-consumer-app-2-0-in-u-s/.
Chan et al. “Wireless Patch Sensor for Remote Monitoring of Heart Rate, Respiration, Activity, and Falls.” pp. 6115-6118. 2013 35th Annual International Conference of the IEEE Engineering in Medical and Biology Society.
Wei et al. “A Stretchable and Flexible System for Skin-Mounted Measurement of Motion Tracking and Physiological Signals.” pp. 5772-5775. 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. Aug. 26, 2014.
Daoud et al. “Fall Detection Using Shimmer Technology And Multiresolution Analysis.” Aug. 2, 2013. URL: https://decibel.ni.com/content/docs/DOC-26652.
Libbus. “Adherent Cardiac Monitor With Wireless Fall Detection For Patients With Unexplained Syncope.” Abstracts of the First AMA-IEEE Medical Technology Conference On Individualized Healthcare. May 22, 2010.
Duttweiler et al., “Probability Estimation In Arithmetic And Adaptive-Huffman Entropy Coders,” IEEE Transactions on Image Processing. vol. 4, No. 3, Mar. 1, 1995, pp. 237-246.
Gupta et al., “An ECG Compression Technique For Telecardiology Application,” India Conference (INDICON), 2011 Annual IEEE, Dec. 16, 2011, pp. 1-4.
Nave et al., “ECG Compression Using Long-Term Prediction,” IEEE Transactions on Biomedical Engineering, IEEE Service Center, NY, USA, vol. 40, No. 9, Sep. 1, 1993, pp. 877-885.
Skretting et al., “Improved Huffman Coding Using Recursive Splitting,” NORSIG, Jan. 1, 1999.
A Voss et al., “Linear and Nonlinear Methods for Analyses of Cardiovascular Variability in Bipolar Disorders,” Bipolar Disorders, votl. 8, No. 5p1, Oct. 1, 2006, pp. 441-452, XP55273826, DK ISSN: 1398-5647, DOI: 10.1111/i.1399-5618.2006.00364.x.
Varicrad-Kardi Software User's Manual Rev. 1.1, Jul. 8, 2009 (Jul. 8, 2009), XP002757888, retrieved from the Internet: URL:http://www.ehrlich.tv/KARDiVAR-Software.pdf [retrieved on May 20, 2016].
Vedapulse UK, Jan. 1, 2014 (Jan. 1, 2014), XP002757887, Retrieved from the Internet: URL:http://www.vedapulseuk.com/diagnostic/ [retrieved on May 19, 2016].
http://www.originlab.com/origin#Data_Exploration 2015.
https://web.archive.org/web/20130831204020/http://www.biopac.com/research.asp?CatID=37&Main=Software (Aug. 2013).
http://www.gtec.at/Products/Software/g.BSanalyze-Specs-Features (2014).
ADINSTRUMENTS:ECG Analysis Module For LabChart & PowerLab, 2008.
BIOPAC Systems, Inc. #AS148-Automated ECG Analysis , Mar. 24, 2006.
Health Research—Hexoskin Biometric Shirt | Hexoskin URL:http://www.hexoskin.com/pages/health-research (Web page cached on Dec. 2, 2014).
Jacob Kastrenakes, “Apple Watch uses four sensors to detect your pulse,” Sep. 9, 2014. URL: http://www.theverge.com/2014/9/9/6126991/apple-watch-four-back-sensors-detect-activity.
Nicole Lee, “Samsung Gear S review: an ambitious and painfully flawed smartwatch,” Dec. 1, 2014. URL: http://www.engadget.com/2014/12/01/samsung-gear-s-review/.
G. G. Ivanov, “HRV Analysis Under The Usage Of Different Electrocardiopraphy Systems,” Apr. 15, 2008 (Apr. 15, 2008), XP55511209, Retrieved from the Internet: URL:http://www.drkucera.eu/upload_doc/hrv_analysis_(methodical_recommendations).pdf [retrieved on Oct. 1, 2018].
May 2, 2022 Letter From Counsel. 1:22-cv-00351-CFC. May 2, 2022.
Dwayne C. Leonard, A Framework for the Creation of a Unified Electronic Medical Record Using Biometrics, Data Fusion and Belief Theory, 2007, https://dialog.proquest.com/professional/docview/304852676/17AEEF1F9382EF1C4E5/6?accountid=131444 (last visited Aug. 27, 2021) (Year: 2007).
May 24, 2022 Letter to Opposing Counsel. 1:22-cv-00351-CFC. May 24, 2022.
Complaint from Case No. 1:22-cv-00351-UNA, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: Mar. 18, 2022, 182 pages.
Defendant's Opening Brief In Support of Its Motion To Dismiss For Failure to State A Claim from Case No. 1:22-cv-00351-CFC, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: May 25, 2022, 18 pages.
Defendant's Answer, Defenses, and Counterclaim from Case No. 1:22-cv-00351-CFC, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: May 25, 2022, 132 pages.
Plaintiff's Answering Brief In Opposition to Defendant's Motion to Dismiss For Failure to State a Claim from Case No. 1:22-cv-00351-CFC, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: Jun. 8, 2022, 25 pages.
Plaintiff's Answer to Defendant's Counterclaim from Case No. 1:22-cv-00351-CFC, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: Jun. 15, 2022, 5 pages.
Defendant's Reply Brief In Support of Its Motion to Dismiss For Failure to State a Claim from Case No. 1:22-cv-00351-CFC, Bardy Diagnostics, Inc. (Plaintiff) v. Vital Connect, Inc. (Defendant), Filed: Jun. 15, 2022, 93 pages.
Oct. 17, 2022 Letter to Opposing Counsel, Bardy Diagnostics, Inc. v. Vital Connect, Inc., No. 22-cv-00351-CFC (D. Del.), Oct. 17, 2022.
Nov. 11, 2022, Letter from Opposing Counsel, 1:22-cv-00351-CJB; Bardy Diagnostics, Inc. v. Vital Connect, Inc. (D. Del.), Nov. 11, 2022.
Dec. 26, 2022 Letter from Opposing Counsel, 1:22-cv-00351-CJB; Bardy Diagnostics, Inc. v. Vital Connect, Inc. (D. Del.); and IPR2023-00381; Vital Connect, Inc. v. Bardy Diagnostics, Inc. (P.T.A.B.), Dec. 26, 2022.
First Amended Complaint for Patent Infringement, 1:22-cv-00351-CJB, Bardy Diagnostics, Inc. v Vital Connect, Inc. (D. Del.), filed Jan. 10, 2023.
Petition for Inter Partes Review of U.S. Pat. No. 11,051,743 Pursuant To 35 U.S.C. §§ 311-319 and 37 C.F.R. §42, Case No. IPR2023-00381, Vital Connect, Inc. v. Bardy Diagnostics, Inc. (P.T.A.B.), Dec. 21, 2022, 875 pages.
Defendant's Answer to First Amended Complaint, Defenses, and Counterclaim, 1:22-cv-00351-CJB, Bardy Diagnostics, Inc. v. Vital Connect, Inc. (D. Del.), filed Jan. 24, 2023 (227 pages).
Related Publications (1)
Number Date Country
20200315489 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
61882403 Sep 2013 US
Continuations (2)
Number Date Country
Parent 16178455 Nov 2018 US
Child 16853667 US
Parent 14080725 Nov 2013 US
Child 15676896 US
Continuation in Parts (2)
Number Date Country
Parent 15832385 Dec 2017 US
Child 16178455 US
Parent 15676896 Aug 2017 US
Child 15832385 US